We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.50
Bid: 12.50
Ask: 13.50
Change: 5.575 (75.08%)
Spread: 1.00 (8.00%)
Open: 9.65
High: 13.50
Low: 9.65
Prev. Close: 7.425
CAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

12 Jul 2023 07:00

RNS Number : 7215F
Carclo plc
12 July 2023
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN

 

 

Carclo plc

 

("Carclo" or the "Group")

 

Unaudited Preliminary Results for the year ended 31 March 2023

 

Carclo plc, a preferred and trusted partner of global customers, providing high-precision critical components to the life sciences, aerospace, specialised optics, and technology industries, announces its results for the financial year ended 31 March 2023 ("FY22/23").

 

The key financial performance measures for the year are as follows:

 

 

 

Year ended

31 March

2023

Year ended

31 March

2022

 

£000

£000

Continuing operations

 

 

Revenue

143,445

128,576

Underlying operating profit

5,939

6,096

Exceptional items

(4,710)

721

Covid-19 related US government grant income

-

2,087

Operating profit

1,229

8,904

Discontinued operations

 

Profit on discontinued operations, net of tax

-

693

 

Underlying earnings per share - basic - continuing operations

0.4p

3.1p

Basic earnings per share - continuing operations

(5.4)p

7.0p

Net debt excluding lease liabilities

22,490

21,535

Net debt

34,360

32,405

IAS 19 retirement benefit liability

34,493

25,979

 

Continuing operations

Revenue

CTP

136,814

123,869

Aerospace

6,631

4,707

Total

143,445

128,576

Underlying operating profit

CTP

7,321

8,393

Aerospace

1,520

677

Central

(2,902)

(2,974)

Total

5,939

6,096

 

 

 

 

 

 

Financial performance:

A shift in strategy prioritising operational performance improvement and increased cash generation against a backdrop of high inflation and rising interest rates.

· Revenue from continuing operations increased by 11.6% (3.8% at constant currency) to £143.4 million (FY21/22: £128.6 million).

· Underlying operating profit from continuing operations £5.9 million (FY21/22: £6.1 million).

· Cash generated from operations was £7.8 million (FY21/22: £6.8 million).

· Statutory operating profit from continuing operations £1.2 million (FY21/22: £8.9 million including £2.1 million one-off credit arising from the forgiveness of US government Covid-19 support loans).

· Net exceptional cost in the year of £4.7 million (FY21/22: £0.7 million gain), reflects £3.4 million rationalisation costs, £0.9 million costs arising from cancellation of future supply agreement, £0.9 million doubtful debt and related inventory provision, £0.3 million costs in respect to legacy claims, partially offset by a £0.8 million gain on disposal of surplus properties.

· Net debt of £34.4 million (31 March 2022: £32.4 million), £1.5 million of the increase is explained by movements in foreign exchange. After increasing in H1, adjusting for currency effects, net debt reduced by £2.1 million during H2, reflecting the start of the delivery of the revised strategy.

 

 

Strategic highlights:

· Fortifying our financial position for long-term success - Optimising resources, enhancing cash flow, and fuelling long-term success.

· Factory specialisation and standardisation - Driving operational excellence for enhanced efficiency and satisfaction.

· Organic growth through strategic partners - Strengthening relationships for mutual success.

· Embracing sustainability for a greener future - Innovating, reducing waste and driving positive environmental impact.

· Empowering unity, driving breakthroughs - Harnessing the power of collaboration, diversity and common purpose to redefine industry standards.

 

 

Sustainability highlights:

· Leading the way in sustainability - Launching of a worldwide initiative "Project Zelda" (Carclo's landmark sustainability initiative) to harness our power to reduce waste, increase energy efficiency and contribute to a greener, more sustainable world and create a positive societal ripple effect via local community involvement.

· Strengthening supply chain sustainability - Uniting with EcoVadis to prioritise sustainability, foster eco-friendly supply chain practices and drive positive environmental change.

· Engaging communities, creating lasting social value - Investing in local communities, fostering social inclusion and supporting initiatives that contribute to long-term societal well-being.

 

 

Commenting on the results, Frank Doorenbosch, Chief Executive Officer said: “This year has undoubtedly presented Carclo with its fair share of challenges, testing our mettle and resilience. However, I am proud to say that we have risen above these obstacles and proven our ability to adapt and thrive in a dynamic and evolving business landscape. Despite the headwinds of inflation, rising interest rates, and other economic challenges, our unwavering commitment to excellence has enabled us to achieve a slight increase in revenue, reaching £143.4 million, an increase of 11.6% on the prior year and 3.8% at a constant currency rate.

Our success can be attributed to our strategic approach, which includes agile pricing adjustments to mitigate the impact of inflation and energy surcharges. Furthermore, our commitment to operational excellence has been exemplified through the implementation of factory specialisation measures, allowing us to enhance efficiency, streamline processes, and optimise our performance across our diverse range of offerings, including Design & Engineering and Manufacturing Solutions.

In addition to navigating economic challenges, we have proactively addressed debt positions, rationalisation costs, and legacy issues, such as the successful settlement of the cancellation of a supply contracted framework agreement. Our improvement in cash conversion underscores our financial resilience and highlights the effectiveness of our strategic initiatives in managing inflation impacts and energy costs.

Looking ahead, I am filled with confidence and optimism for Carclo’s future. Our strategy, centered around factory specialisation, process standardisation, operational excellence, financial stability, and sustainability, positions us for continued success. I am immensely grateful to the exceptional Carclo team whose unwavering dedication and relentless pursuit of excellence have propelled us forward in this challenging year. Together, we will continue to achieve positive results and drive our ongoing success.”

Further Information

Please contact:

 

Frank Doorenbosch, Chief Executive Officer, Carclo plc

+44 (0)1924 268040

David Bedford, Chief Financial Officer, Carclo plc

+44 (0)1924 268040

 

 

 

Forward-looking statements 

Certain statements made in this annual report and accounts are forward-looking statements. Such statements are based on current expectations and are subject to a number of risks and uncertainties that could cause outcomes to differ materially from those expected.

Alternative performance measures 

Alternative performance measures are defined in the glossary on page 46. A reconciliation to statutory numbers is included on page 45. The Directors believe that alternative performance measures provide a more useful comparison of business trends and performance. The term “underlying” is not defined under IFRS and may not be comparable with similarly titled measures used by other companies.

 

 

 

Chief Executive Officer Review

Introduction

As I look back on the past financial year, it is evident that Carclo encountered a range of external challenges that required us to be resilient and adaptable. Yet, we approach the future with unwavering optimism. Despite the obstacles we faced, we have embraced a strategic transformation, and we are already witnessing promising early signs of progress. Our steadfast strategy, supported by a revitalised leadership team, sets the stage for long-lasting success and sustainability. 

 

The year in review

 

The past fiscal year presented us with numerous challenges, including rising debt costs, significant increases in input expenses, reduced demand for Covid-19 testing products and a tight labour market in key manufacturing locations. These hurdles prompted us to embark on a strategic transformation and reinforce our leadership team. As part of this transformative journey, we take pride in highlighting the increased diversity within our Board and senior executive team. We firmly acknowledge that diversity brings valuable fresh perspectives, fosters innovation and enhances decision-making.

 

Our strategic transformation focuses on operational excellence, robust financial health and the standardisation of processes and equipment to optimise asset utilisation, enhance efficiency and reduce complexity. We are energised and committed to deliver exceptional value to all stakeholders. Additionally, we are dedicated to sustainability, aiming to reduce waste and energy consumption while actively engaging with local communities.

Despite the economic challenges we faced, our revenues demonstrated resilience, increasing 3.8% at constant currency. This growth can be attributed to our successful collaboration on growth projects with our strategic customers. However, our margins, particularly in the CTP division, were impacted by time delay of passing on higher input costs. In addition, we absorbed some of these costs to uphold our commitment to our valued customers.

 

Encouragingly, we are beginning to witness the positive outcomes of our strategic actions, particularly within our EMEA manufacturing solutions business. This has resulted in stronger margins in the latter half of the year. The final quarter of FY22/23 revealed promising results from our new strategy where our EMEA manufacturing platform showcased improved operational performance in the second half of FY22/23, with higher asset utilisation and increased cash generation. These positive developments underline the effectiveness of our strategic approach.

 

Although our overall underlying operating profit performance for the year amounted to £5.9 million, which was lower than the previous year’s figure (FY21/22: £6.1 million), it is important to note that these results were achieved within a demanding economic climate. Despite the challenges, we remained focused on profitability and positioning the company for future growth.

 

The restructuring costs associated with our strategic shift were substantial but necessary for the long-term sustainability of our business. While we faced these challenges, we managed to improve our cash conversion rate from 42.6% in FY21/22 to 84.0% in FY22/23. As a result, our net debt at the end of the year remained relatively stable, compared to the previous year-end, considering constant currency factors. This achievement is particularly commendable given our ongoing commitments to bank interest, pension contributions, and growth capital expenditures.

 

I am delighted to report that the implementation of our new strategy and our focused efforts on cash generation yielded positive results. We were able to generate robust operational cash in the second half of the year, which significantly improved our position compared to the figures as of 30 September 2022. Since March 31, 2023, we have repaid £3.7 million of term loans ahead of schedule and reduced our RCF balance from £3.5 million to £2 million, leaving £1.5 million undrawn as of the end of June 2023.

 

These achievements underscore our dedication to strengthening our financial position and maintaining a solid foundation for future growth. Despite the challenges we faced, our commitment to effective financial management and cash generation strategies has paid off, positioning us favourably as we move forward.

Strategy

Recognising the shifting dynamics of our business environment, we have undertaken a rigorous strategic review. The result is a renewed blueprint for Carclo’s future, one that is flexible, robust and aligned with our mission.

 

At the heart of our strategy lies an uncompromising commitment to the safety and well-being of our workforce, customers and communities. We firmly believe that our success is underpinned by the health and prosperity of all our stakeholders. Hence, protecting and fostering this is not just a priority, it’s woven into our operational DNA.

 

Recognising the evolving dynamics in our business environment, the core of our strategy is anchored on operational excellence and robust financial health. Central to our tactical blueprint is the group-wide standardisation of our processes and equipment, an initiative aimed at optimising asset utilisation, enhancing efficiency, and reducing the cost of complexity.

 

In the short term, our focus is on achieving stability and maximising return from our existing resources. To that end, we are instituting stringent asset management practices including meticulous tracking, optimised deployment, and regular performance reviews, coupled with an investment in cost-efficient technologies and process improvements. By simplifying operations, we are effectively reducing the cost of complexity, increasing our agility and responsiveness.

 

In parallel, we’re fostering an ethos of knowledge-sharing and cross-functional collaboration to disseminate and implement best practices throughout the organisation. This strategic blend of resource maximisation, process standardisation, and collective learning not only drives up operational performance and reduces costs, but also enhances employee and customer satisfaction through the consistent and reliable delivery of high-quality products and services.

 

Our new direction includes a keen focus on product and factory specialisation, allowing each of our facilities to hone in on their unique strengths and minimise the cost of complexity. This approach sharpens our focus, ramps up efficiency, and elevates performance, thereby ensuring we deliver seamlessly to our global clientele across the entire gamut of our offerings – Design & Engineering and Manufacturing Solutions.

 

Our long-run facilities are 100% geared towards process optimisation and integrating advanced back-end automation, thereby enhancing throughput and quality. On the other hand, our medium-run facilities are tasked with increasing their agility, efficiently managing changeovers between runs and developing flexible automation systems to ensure continuity and productivity. The first region where we have completed the factory specialisation is EMEA, where the strategy is delivering the expected results. The next region we are addressing is the USA, albeit with different dynamics, where the focus will allow us to build a winning model. 

 

We are keen to shape Carclo into an engaging organisation with high energy drive, committed to high quality execution, when precision matters. To be ready to meet the evolving demands of our customers and the marketplace. Our strategy includes diversifying our portfolio whilst aiming for steady top-line growth.

 

We are committed to fortifying our balance sheet and decreasing our debt, with an emphasis on cash generation, prudent management of working capital and enhancing equipment utilisation. We are channelling our capital investments towards measures that improve safety, efficiency, yield and quality. Through enhanced project flexibility, leveraging on our well invested but underutilised machine park we will deliver growth.

 

When it comes to pricing, we are not racing to the bottom. Instead, we are committed to delivering exceptional value, underpinned by the high-quality and comprehensive support we offer.

 

Our team forms the heart of Carclo, their growth being a cornerstone of our strategy. We’re prioritising investments in their professional enhancement, creating dedicated Educational and Excellence Centres regionally. This initiative empowers our engineers with robust training and skills development programs, propelling process enhancements, automation advancements, and innovative product line creation. We believe that nurturing their talents and fostering a culture of innovation will be pivotal to our collective success. 

 

As part of our commitment to sustainability, we’ve launched our worldwide initiative, “Zelda”. Its primary objectives are to reduce waste sent to recycling by 50% within two years and decrease energy consumption per unit of production by 15% over three years through energy optimisation. Moreover, we are devoted to creating a positive societal ripple effect via local community involvement. 

 

We believe in being candid about our sustainability journey, and will consistently share updates on our achievements, challenges, and milestones.

 

 

 

Divisional performance

CTP Division

We have divided our CTP division into two separate businesses. Our Design & Engineering business is responsible for handling global customer development projects, while our Manufacturing Solutions business comprises our worldwide network of facilities, specialising in a comprehensive range of manufacturing services, encompassing injection moulding, assembly and supply chain solutions. Our CTP division has undertaken a substantial restructuring effort in the EMEA region to better align with customer needs and successfully navigate challenges such as rising input costs and labour shortages. The execution of our strategy, which includes standardising machines, processes, and global quality standards, coupled with clear factory specialisation, has revitalised our operational results in the region. We are now focused on implementing these strategies in the US region to further strengthen our position.

 

Through an unwavering commitment to operational excellence and a customer-centric approach, we are dedicated to achieving sustained profitability and creating long-term value. These principles guide our actions as we strive to exceed customer expectations, drive efficiency, and optimise our performance. By aligning our operations with customer needs and consistently delivering exceptional products and services, we aim to re-establish Carclo as a trusted industry leader and maximise value for our stakeholders.

 

Design & Engineering (D&E)

In FY22/23, our Design & Engineering (D&E) business demonstrated robust revenue performance, generating total revenues of £20.1 million. While sales were lower compared to last year’s exceptional figures, they remained significantly higher than the average of the previous three years. This reflects the strength of our ongoing focus on the life sciences sector and strategic partnerships with existing customers.

 

By maintaining this strategic direction, we built a strong order book by the end of the year, positioning us favourably for continued success in the future. This is a testament to our ability to deliver value-added solutions and meet the evolving demands of our clients.

 

To further augment our capabilities and support our technical talent, we are establishing a state-of-the-art training facility at our Roseytown location in Pennsylvania. This facility serves as a dedicated space not only for validation purposes but, more importantly, for in-house training on manufacturing lines, mould technology, and material behaviour. It enables our team to continually refine their skills and expertise, empowering them to consistently deliver best-in-class solutions to our valued clients. This investment in our team’s development reinforces our commitment to excellence and ensures that we stay at the forefront of innovation in the industry.

 

Manufacturing Solutions (MS):

Our Manufacturing Solutions (MS) business serves as our global manufacturing and assembly platform, strategically divided into three regions: Americas, EMEA, and APAC. We have embarked on a focused journey of factory specialisation, emphasising operational excellence and minimising the complexities that arise in manufacturing processes.

 

In the first phase of our EMEA strategic reset, we are already witnessing the potential of our manufacturing platform through enhanced operational efficiency, increased asset utilisation, and improved labour efficiency. These early successes reinforce our confidence in the effectiveness of our strategic approach. In the Americas, our leadership team faces challenges posed by input cost increases and labour shortages. Addressing these challenges remains our team’s primary focus, and we are intensifying our efforts to execute the strategic positioning and factory specialisation of our US manufacturing platform.

 

Despite the hurdles faced, the MS business achieved modest revenue growth in FY22/23 at constant currency. Our revenues increased to £116.7 million (£104.9 million at constant currency). This growth was primarily driven by customer price increases that offset inflationary pressures and higher energy costs. By diligently managing these factors, we were able to maintain a positive revenue trajectory while navigating a challenging market environment.

 

Through our steadfast commitment to operational excellence and strategic focus on factory specialisation, we are confident in our ability to enhance our MS business’ performance, drive efficiencies, and maximize value for our stakeholders.

 

 

Aerospace Division

The Aerospace division has demonstrated a remarkable improvement in profit performance year-on-year, benefiting from the post-Covid-19 market recovery. Our revenue experienced impressive growth, reaching £6.6 million in the current fiscal year compared to £4.7 million in FY21/22, representing a substantial increase of 40.9%. This resurgence in the Aerospace Division’s performance is highly encouraging, highlighting our ability to adapt and thrive in evolving market conditions.

 

While our progress in the Aerospace Division is noteworthy, we did experience some challenges in our cash conversion rate due to constraints within the supply chain of specialised metals. However, our commitment to delivering high-quality products and services remains unwavering, positioning us for continued success and growth in the aviation industry.

 

With the aviation sector on an upswing, we are well-positioned to leverage this positive momentum. Our dedication to excellence, combined with our relentless focus on meeting customer expectations, enables us to capitalise on the opportunities that lie ahead. As we navigate challenges and pursue opportunities, we remain committed to maintaining our reputation as a trusted provider of superior products and services in the aerospace market.

 

Financing

Given the impact of rising interest rates and the high inflationary environment, we have worked closely with our lending bank to secure appropriate ongoing financial support for the business. We are pleased that we continue to be supported by the bank who have agreed to a more appropriate set of covenants during the period whilst we revitalise the business and implement our new strategy. After receiving written confirmation from the bank we are now awaiting the formal documentation to be signed, which is expected to be completed before the publication of the Group’s Annual Report and Accounts.

 

Sustainability and Corporate Responsibility

We have clearly defined our sustainability strategy in our worldwide initiative “Project Zelda”. We are first addressing the major contributors to our ecological footprint, being raw material and electricity usage. The team is focused on delivering a sustainable improvement in reducing, reusing and upcycling the materials used within our production processes. Overall targets to be reached in two years are:

 

A 50% reduction of materials we send to recycling.A 10% reduction of the amount of KwH per kilo of products sold.

 

We are enhancing our various community engagement initiatives, we have continued to invest in the growth and development of the regions in which we operate, creating opportunities for education, skill development, and employment.

Moving forward

 

The past year presented us with significant challenges, but it also marked a transformative period of renewed focus. We have implemented a new strategy, formed a new board, and established a diverse and dynamic leadership team, all fuelled by a high level of energy and unwavering commitment to our employees and customers. While there is still much work ahead, the early results from our new strategy are promising, instilling a sense of optimism and belief in a bright future.

 

Our positive outlook is supported by compelling evidence. We have successfully renegotiated our banking covenants, securing financial stability as we continue to implement our new strategic approach. Significant progress has been made in our Mitcham operations, further strengthening our confidence in the effectiveness of our initiatives. Furthermore, we have successfully reached a settlement agreement with the cancellation of a supply contract, reinforcing our ability to navigate challenges and capitalise on opportunities.

 

In conclusion, we acknowledge that FY22/23 presented its fair share of difficulties. However, we have already embarked on a new chapter and are turning the page towards a future brimming with possibilities. We have full confidence in our new strategy and leadership team, feeling that the best is yet to come. We extend our heartfelt appreciation to the staff at Carclo for their ongoing support during this transformative time. Together, we will navigate this transition and forge a path towards sustained success.

 

Frank Doorenbosch

 

Chief Executive Officer

 

11 July 2023

 

Finance review 

Our new strategy places a greater emphasis on operational performance improvement and cash generation in response to the challenges posed by high inflation and rising interest costs.

 

As we reflect on the past fiscal year, it's heartening to see how our Group has navigated the economic landscape, delivering a robust 11.6% growth in revenue (£143.4 million), or a solid 3.8% at constant currency, up from £128.6 million in FY21/22. This demonstrates not only the resilience of the markets we serve, but also the strength and continuity of our key customer relationships.

 

Our underlying operating profit came in at £5.9 million, compared to £6.1 million (or £6.7 million at constant currency) in the previous year, resulting in a return on sales of 4.1%, down slightly from 4.7% last year. This shift in profitability was primarily influenced by escalating cost inflation, most notably a sharp increase in energy costs, and the challenge these pose in terms of timely pass-through to customers.

 

Exceptional net costs for the year amounted to £4.7 million, compared to £1.4 million gain in FY21/22. The majority of these costs, £3.4 million to be exact, were cash settled. These costs encompassed £3.4 million in rationalisation expenses, £0.9 million stemming from the termination of future supply agreements, £0.9 million in doubtful debt and associated inventory provision, and £0.3 million related to legacy health claims. These costs were partly offset by a gain of £0.8 million from the disposal of surplus properties.

 

Overall, the financial year proved to be challenging but also demonstrated the Group's resilience and adaptability. Moving forward, we continue to focus on our commitment to creating long-term shareholder value and maintaining the trust of our strategic customers.

 

Statutory operating profit is down £7.7 million on prior year to £1.2 million (FY21/22: £8.9 million).

 

During the year, we experienced an increase in net finance costs, primarily due to rising interest rates, which amounted to £3.7 million (FY21/22: £3.0 million). This figure includes notional pension deficit interest charged of £0.7 million (FY21/22: £0.7 million).

 

Taxation charge for the year was £1.4 million (FY21/22: £0.8 million). The FY21/22 taxation charge benefited from a deferred tax credit of £0.7 million, being the recognition of a deferred tax asset on the UK projected profits at the time. However, this year, we have seen the reversal of that deferred tax asset due to the effects of the restructuring plans.

 

Statutory loss/profit after tax was £4.0 million loss (FY21/22: £5.8 million profit) on all operations, and £4.0 million loss (FY21/22: £5.1 million profit) on continuing operations, giving a statutory loss per share on all operations of 5.4 pence (FY21/22: 7.9 pence profit), and 5.4 pence loss on continuing operations (FY21/22: 7.0 pence profit).

Underlying profit after tax fell to £0.3 million (FY21/22: £2.3 million), giving an underlying EPS of 0.4 pence (FY21/22: 3.1 pence), on underlying operating profit of £5.9 million, down 2.6% on prior year (FY21/22: £6.1 million).

Cash generated from operations was £7.8 million and 14.7% higher than the prior year (FY21/22: £6.8 million), reflecting the change in strategy from a focus on top-line growth to cash generation via operational improvements and robust working capital control. Efficient management of working capital is a key contributor to cash performance. In addition, during the year a sale and leaseback raised £2.4 million after costs.

 

Cash generated by the Group was principally utilised to make capital investment and lease repayments, pension deficit repair contributions, scheduled bank loan repayments and interest payments. The Group’s full cashflow statement is set out on page 18. 

 

In recognition of the shift in strategic priorities we have refreshed the Group’s key externally reported KPIs to those which we consider will best demonstrate the progress being made towards achieving our strategic goals. These are set out on pages 26 and 27 of the Annual Report and Accounts.

A reconciliation of statutory to underlying non-GAAP financial measures is provided on page 45.

 

 

 

Net debt

During the year, we redirected our investment in capital expenditure towards a rapid payback, focussing on our continuous improvement strategy aimed at supporting asset performance and utilisation. Tangible additions were £5.8 million (FY21/22: £9.7 million) mainly in support of major customer programmes. Of this investment, £3.5 million (FY21/22: £6.8 million) was delivered via leasing.

Net debt, including IFRS16 lease liabilities, increased in the year by £2.0 million to £34.4 million (FY21/22: £32.4 million). Of this increase £1.5 million was due to foreign currency movements. Net debt excluding leases increased £1.0 million to £22.5 million (FY21/22: £21.5 million). Following the shift in strategic focus, improvements in our cash generation have resulted in a reduction of net debt including lease liabilities during H2 of £2.5 million.

 

CTP division

CTP revenue of £136.8 million was up 10.5% (2.5% at constant currency) (FY21/22: £123.9 million) with underlying volumes broadly flat.

CTP divisional operating profit before exceptional items was £7.3 million, £1.1 million down on the prior year, excluding £2.1 million of non-recurring income in the form of a US government Covid-19 grant.

In the face of high cost inflation, particularly in labour and energy prices, our CTP division encountered significant hurdles. The tightened labour markets, predominantly in the US, imposed further complications in the recruitment and retention of labour. These challenges underline the rapidly changing economic conditions we find ourselves grappling with, and underscore the necessity of our ongoing strategic adaptations. Although there were delays in passing on the impact of inflation to customers, CTP made significant progress during H2 in implementing both temporary energy surcharges and permanent pricing increases, resulting in an improved margin performance, particularly in the final quarter of the year.

The Group was met with an unforeseen development in December 2022 when a prospective new global OEM customer informed us, following the completion of the design and engineering phase, due to a contraction in the end-market demand for Covid-19 testing, the customer decided to suspend progression into the production phase of the original ten-year Framework Agreement. However, we moved swiftly and strategically to mitigate potential financial implications. On 30 May 2023, we successfully signed a settlement agreement that effectively neutralises the Group's financial exposure arising from the premature termination of this contract. This settlement is a testament to our resilience and flexibility in navigating unexpected circumstances.

Furthermore, we were able to quickly pivot and rapidly implement a plan to repurpose the production capacity assigned to this project. The majority of the capital investments, inclusive of infrastructure such as buildings, clean rooms, and state-of-the-art equipment have been reallocated to enhance projects with existing strategic partners. We also signed a mutually satisfactory settlement agreement with the customer concerning working capital and recompense for business disruption.

There is a considerable potential to elevate CTP's operational performance even further, and we have taken steps to seize this opportunity. We've initiated fresh strategies designed to bolster both asset utilisation and our ability to meet customers' needs through factory specialisation. Our commitment to ceaseless improvement propels these initiatives, backed by the recent implementation of real-time operational data capture and reporting systems. This approach enables us to react more swiftly to developments, continuously refine our operations, and maintain our mission of delivering superior customer value.

 

Aerospace division

In the Aerospace sector, we saw an impressive uptick in revenue to £6.6 million, a surge of 40.9% (or 39.4% at constant currency), compared to £4.7 million in FY21/22. This marks a return to near pre-Covid-19 levels for this division, an accomplishment underpinned by strong operating profitability of £1.5 million for the year, more than doubling the prior year's £0.7 million. The market has demonstrated a robust recovery, and we have been agile in leveraging this momentum, securing increased order volumes predominantly from our existing customer base. Our strategy to strengthen and deepen relationships with these customers has evidently paid off, underlining the importance of customer retention in our overall growth plan.

Central costs

In terms of our overheads, we have seen a minor reduction in other Group and central underlying costs, which amounted to £2.9 million for this fiscal year, compared to £3.0 million in FY21/22. This slight decrease reflects our ongoing commitment to prudent cost management and operational efficiency. We will continue to seek ways to streamline our central expenses without compromising our quality of service we deliver to the business.

Total Group

Bank facilities

On 2 September 2022 the Group successfully refinanced the facilities with the Company's lender, concluding a first amendment and restatement agreement relating to the multicurrency term and revolving facilities agreement dated 14 August 2020.

As at 31 March 2023, total UK bank facilities were £32.8 million, of which £3.5 million related to a revolving credit facility (maturing on 30 June 2025) and £29.3 million in term loan facilities. £1.4 million of the term facility will be amortised by 31 March 2024 and a further £2.2 million by 31 March 2025. The balance becomes payable by the maturity date, 30 June 2025.

As previously reported at the half-year, increasing interest rates had limited the headroom on the Group's banking covenants, principally interest cover, which prompted the Group to seek an adjustment of its banking covenants to ensure sufficient funding.

Since then, we have worked closely with our bank, who have remained supportive throughout, and agreed to adjust the interest cover covenant at both the December 2022 and March 2023 testing points. As announced on 23 June 2023, we are pleased to confirm that we have now agreed on revised covenants covering the period to maturity at 30 June 2025, providing the required level of certainty over our funding.

 

Moving forward, the Group remains committed to prioritising the strengthening of its balance sheet and seeking alternative sources of bank financing for its growing US operations in the medium term. We will continue to closely monitor market conditions and work proactively with our bank to ensure our ongoing financial stability and success.

 

Defined benefit pension scheme actuarial valuation

 

The last triennial actuarial valuation of the Group pension scheme was carried out as at 31 March 2021. This reported a significantly reduced actuarial technical provisions deficit of £82.8 million (FY21/22: £90.4 million based upon the 31 March 2018 valuation).

 

The statutory accounting method of valuing the Group pension scheme deficit under IAS 19 resulted in an increase in the net liability to £34.5 million at 31 March 2023 (31 March 2022: £26.0 million).

 

Over the year, the Group’s contributions to the scheme were £4.1 million (FY21/22: £3.9 million).

 

During the year there was significant volatility in investment markets with bond and gilt yields spiking in the aftermath of the September 22 “mini budget”. The pension, which was maintaining an 80% liability hedge via Liability Driven Investments (“LDI”) and bond holdings, experienced a significant fall in the value of these assets, albeit less than the fall in the equivalent of the liabilities being hedged. Other scheme assets including property and global equity funds also experienced negative returns during the period with the resulting increase in the IAS 19 deficit.

 

Treasury

 

The Group faces currency exposure on its overseas subsidiaries and on its foreign currency transactions. In addition, as set out in the principal risks and uncertainties as presented in the Annual Report and Accounts, the plc is reliant on regular funding flows from the overseas subsidiaries to meet banking, pension and administrative commitments. To manage this complexity, we have enhanced the Group’s management of cash, debt and exchange risks by strengthening our treasury function.

 

The Group reports trading results of overseas subsidiaries based on average rates of exchange compared with sterling over the year. This income statement translation exposure is not hedged as this is an accounting rather than cash exposure and as a result the income statement is exposed to movements in the US dollar, euro, renminbi, Czech koruna and Indian rupee. In terms of sensitivity, based on the FY22/23 results, a 10% increase in the value of sterling against these currencies would have decreased reported profit before tax by £0.8 million.

 

Dividend

 

Given the restrictions on the payment of dividends contained within the amended and restated bank facilities agreement and the absence of distributable reserves required to make dividend payments, the Board is not recommending the payment of a dividend for the financial year FY22/23 (FY21/22: £nil). Under the terms of the restructuring agreement, the Group is not permitted to make a dividend payment to shareholders up to the period ending June 2025.

 

Alternative performance measures

 

In the analysis of the Group’s financial performance, position, operating results and cash flows, alternative performance measures are presented to provide readers with additional information. The principal measures presented are underlying measures of earnings including underlying operating profit, underlying profit before tax, underlying profit after tax, underlying EBITDA and underlying earnings per share.

 

This results statement includes both statutory and adjusted non-GAAP financial measures, the latter of which the Directors believe better reflect the underlying performance of the business and provides a more meaningful comparison of how the business is managed and measured on a day-to-day basis. The Group’s alternative performance measures and KPIs are aligned to the Group’s strategy and together are used to measure the performance of the business and form the basis of the performance measures for remuneration. Underlying results exclude certain items because, if included, these items could distort the understanding of the performance for the year and the comparability between the periods. A reconciliation of the Group’s non-GAAP financial measures is shown on page 45.

 

We provide comparatives alongside all current year figures. The term “underlying” is not defined under IFRS and may not be comparable with similarly titled measures used by other companies.

 

All profit and earnings per share figures relate to underlying business performance (as defined above) unless otherwise stated. A reconciliation of underlying measures to statutory measures for FY22/23 is provided below: 

 

 

 

 

 

 

 

 

 

 

Exceptional

 

£000

 

 

Statutory

items

Underlying

CTP operating profit 

 

 

4,569

(2,752)

7,321

Aerospace operating profit 

 

 

1,520

-

1,520

Central costs 

 

 

(4,860)

(1,958)

(2,902)

Group operating profit from continuing operations

 

 

1,229

(4,710)

5,939

Net finance expense 

 

 

(3,749)

-

(3,749)

Group (loss) / profit before taxation from continuing operations

 

 

(2,520)

(4.710)

2,190

Taxation expense

 

 

(1,437)

-

(1,437)

Group (loss)/profit for the period from continuing operations

 

 

(3,957)

(4,710) 

753

Profit on discontinued operations, net of tax

 

 

-

-

-

Group (loss) / profit for the period

 

 

(3,957)

(4,710) 

753

Basic (loss) / profit per share (pence) 

 

 

(5.4)p

(5.8)p

0.4p

The exceptional items comprise:

 

 

 

 

£000

 

 

Group 1

Restructuring and rationalisation costs

 

 

(3,404)

Costs arising from cancellation of future customer supply agreement

 

 

(877)

Doubtful debt and related inventory provisions

 

 

(896)

Costs in respect to legacy health related claims

 

 

(302)

Profit on disposal of surplus property

 

 

769

Total exceptional items

 

 

(4,710)

 

1There were no exceptional items in respect to discontinued operations in the year to 31 March 2023.

 

Post balance sheet events and going concern

Post balance sheet events

 

Upon completion of the Design and Engineering phase of our supply contract, we received an unexpected notice from a leading global OEM customer in December 2022. Citing a decline in the end-market demand for Covid-19 testing, they chose not to advance into the project's production phase. However, by 30 May 2023, we reached a settlement agreement that largely mitigates the financial risk the Group faced due to the early termination of the contract. The Group has recognised an exceptional cost in the year to 31 March 2023 of £0.9 million, most of which is to recognise assets on balance sheet at recoverable amount, see note 6 for further details. The Group will recognise an exceptional gain in the income statement to 31 March 2024 of approximately £0.6 million. Although the details of the agreement remain confidential, full and final settlement was received on 21 June 2023.

 

On 22 June 2023 the Group’s lending bank, agreed to an adjustment of the interest and the net leverage covenants related to the facilities due to mature on 30 June 2025. On 1 June 2023, a voluntary repayment of £0.4 million was made and on 30 June 2023, a further voluntary repayment of £3.3 million was made.

 

Going concern

The financial statements are prepared on the going concern basis.

 

Group performance during the year has enabled capital investment to be made whilst retaining a stable financial position with net debt excluding lease liabilities as of 31 March 2023 increasing to £22.5 million (31 March 2022: £21.5 million).

 

Net debt including lease liabilities at 31 March 2023 was £34.4 million (31 March 2022: £32.4 million), with the principal reason behind the increase being foreign exchange movements of £1.5 million.

 

On 2 September 2022, the Group successfully refinanced with the Company's bank, concluding a first amendment and restatement agreement relating to the multi-currency term and revolving facilities agreement dated 14 August 2020. The debt facilities available to the Group at 31 March 2023 comprise a term loan of £29.3 million, of which £1.4 million will be amortised by 31 March 2024 and a further £2.2 million amortised by 31 March 2025. The balance becomes payable by the termination date, 30 June 2025.

At 31 March 2023, the term loans were denominated as follows: sterling 14.2 million, US dollar 13.3 million and euro 4.9 million. The facility also includes a £3.5 million revolving credit facility, denominated in sterling, maturing on 30 June 2025.

 

Since the year-end there have been no significant changes to the Group's liquidity position. The term loan balances stood at sterling 10.2 million, US dollar 13.3 million and euro 4.9 million, totalling £27.0 million on 30 June 2023, with undrawn facilities of £1.5 million on the RCF. 

As part of the original bank financing in August 2020 the Group became subject to four bank facility covenant tests. The quarterly covenants to be tested are:

Underlying interest cover;Net debt to underlying EBITDA;Core subsidiary underlying EBITA; andCore subsidiary revenue.

Core subsidiaries are defined as Carclo Technical Plastics Ltd; Bruntons Aero Products Ltd; Carclo Technical Plastics (Brno) s.r.o; CTP Carrera Inc and Jacottet Industrie SAS, with CTP Taicang Co. Ltd and Carclo Technical Plastics Pvt Co Ltd being treated as non-core for the purposes of these covenants.

Following a more than doubling of the base rate in the first half of FY22/23, the Group reassessed its forecasts and concluded there was insufficient headroom available to meet all the agreed banking covenants in the event of certain downside scenarios taking place. Breach of any of these covenants could lead to the creditors calling in their debt, leaving the plc insolvent. As a result, at the half year, in recognition of a potential covenant breach, the Group issued a material uncertainty warning over its ability to continue trading as a going concern. 

Since that time the Group has worked with the bank to amend the covenants and agreed adjustments to the Group’s interest cover covenant for both the December 2022 and March 2023 testing points. 

In December 2022 the Group announced the cancellation of a new business contract that would materially impact the results for FY22/23. Further discussions were held with the bank and, following a review of the Group’s 3-year plan up to March 2026, on 22 June the bank agreed in writing to the Group’s request to further amend the interest cover covenant to June 2025 and to an adjustment to the net debt to underlying EBITDA covenant to December 2023.

The revised banking covenants and thresholds are assumed to be in place throughout the going concern assessment period. However, there remains a material uncertainty over going concern until the formal documentation is signed, which is expected to be completed before the publication of the Group’s Annual Report and Accounts. A schedule of contributions is also in place with the pension trustees with an agreed £3.5 million to be paid annually until 31 October 2039. Additional contributions also agreed are 25% of any surplus of 2023/24 underlying EBITDA over £18 million payable from 30 June 2024 to 31 May 2025, extending to 26% of any 2024/25 surplus payable from 30 June 2025 to 31 May 2026.

In addition, the pension scheme has the benefit of a fifth covenant to be tested each year up to and including 2023. The test requires any shortfall of pension deficit recovery contributions when measured against Pension Protection Fund priority drift (which is a measure of the increase in the UK Pension Protection Fund's potential exposure to the Group's pension scheme liabilities), to be met by a combination of cash payments to the scheme, plus a notional (non-cash) proportion of the increase in the underlying value of the CTP and Aerospace segments based on an EBITDA multiple for those businesses which is determined annually. This test will be completed on the 31 March 2023 audited financial statements and management expect this covenant to be met.

 

The Group is subject to a number of key risks and uncertainties, as detailed in the Principal risks and uncertainties section in the Annual Report and Accounts. Mitigation actions are also considered in this section. These risks and uncertainties have been considered in the base case and severe downside sensitivities and have been modelled accordingly.

The Directors have reviewed cash flow and covenant forecasts to cover the period, at least twelve months from date of signing the consolidated financial statements, considering the Group's available debt facilities and the terms of the arrangements with the Group's bank and the Group pension scheme.

The base case forecast includes assumptions around sales, margins, working capital and interest rates. The sensitivity analysis has considered the risks facing the Group and has modelled the impact of each in turn, as well as considering the impact of aggregating certain risk types and shows that the Group is able to operate within its available facilities and meet its agreed covenants as they arise. Furthermore, the Directors have reviewed sensitivity testing, modelling a range of severe downside scenarios. These sensitivities attempt to incorporate identified risks set out in the Principal risks and uncertainties section of the Annual Report and Accounts.

Severe downside sensitivities modelled included a range of scenarios modelling the financial effects of loss of business from: discrete sites, an overall fall in gross margin of 1% across the Group, a fall in Group sales of 3% matched by a corresponding fall in cost of sales of the same amount, and interest rate risk. 

The Group is not exposed to vulnerable sectors or vulnerable countries but does have certain key customers, which create risks and uncertainties. These risks and uncertainties are documented and the mitigating actions being taken are covered in detail in the Principal risks and uncertainties section in the annual report and accounts.

 

On the basis of this forecast and sensitivity testing, the Board has determined that it is reasonable to assume that the Group will continue to operate within the facilities available and will be able to adhere to the covenant tests to which it is subject throughout at least the twelve-month period from the date of signing the financial statements. 

Accordingly, these financial statements are prepared on a going concern basis. 

David Bedford

Chief Financial Officer

 

 

 

11 July 2023

 

 

 

Consolidated income statement 

for the year ended 31 March 2023

FY22/23

FY21/22

 

 

Notes

£000

£000

Continuing operations:

Revenue

4

143,445

128,576

 

 

Underlying operating profit

5,939

6,096

 

Covid-19 related US government grant income

7

 

-

 

2,087

Exceptional items

6

(4,710)

721

 

 

Operating profit

4

1,229

8,904

Finance revenue

218

77

Finance expense

8

(3,967)

(3,066)

(Loss) / profit before tax

(2,520)

5,915

Income tax expense

9

(1,437)

(809)

(Loss) / profit after tax but before profit on discontinued operations

(3,957)

5,106

Discontinued operations: 

Profit on discontinued operations, net of tax

5

-

693

(Loss) / profit for the period

(3,957)

5,799

Attributable to: 

Equity holders of the Company

(3,957)

5,799

Non-controlling interests

-

-

(3,957)

5,799

(Loss) / Earnings per ordinary share

10

Basic - continuing operations

(5.4)

p

7.0

p

Basic - discontinued operations

-

p

0.9

p

Basic

(5.4)

p

7.9

p

Diluted - continuing operations

(5.4)

p

6.9

p

Diluted - discontinued operations

-

p

0.9

p

Diluted

(5.4)

p

7.9

p

Consolidated statement of comprehensive income

for the year ended 31 March 2023

FY22/23

FY21/22

 

 

 

 

£000

£000

(Loss) / profit for the period

(3,957)

5,799

Other comprehensive (expense) / income 

Items that will not be reclassified to the income statement

Remeasurement (losses) / gains on defined benefit scheme

(10,577)

8,480

Deferred tax arising

-

-

Total items that will not be reclassified to the income statement

(10,577)

8,480

Items that are or may in the future be classified to the income statement

Foreign exchange translation differences

1,129

1,840

Net investment hedge

818

440

Deferred tax arising

(190)

(127)

Total items that are or may in the future be classified to the income statement

1,757

2,153

Other comprehensive (expense) / income, net of tax

(8,820)

10,633

Total comprehensive (expense) / income for the year

(12,777)

16,432

Attributable to -

Equity holders of the Company

(12,777)

16,432

Non-controlling interests

-

-

Total comprehensive (expense) / income for the period

(12,777)

16,432

Consolidated statement of financial position

as at 31 March 2023

FY22/23

FY21/22

 

 

Notes

£000

£000

Non-current assets

Intangible assets

12

23,463

22,714

Property, plant and equipment

13

45,321

46,964

Deferred tax assets

1,185

1,403

Trade and other receivables

-

115

Total non-current assets

69,969

71,196

Current assets

 

Inventories

15,203

16,987

Contract assets

5,763

7,700

Trade and other receivables

21,383

19,702

Cash and cash deposits

10,354

12,347

Non-current assets classified as held for sale

14

-

266

Total current assets

52,703

57,002

Total assets

122,672

128,198

Non-current liabilities

Loans and borrowings

15

39,668

41,804

Deferred tax liabilities

4,917

4,878

Contract liabilities

-

3,099

Retirement benefit obligations

16

34,493

25,979

Total non-current liabilities

79,078

75,760

Current liabilities

 

Loans and borrowings

15

5,046

2,948

Trade and other payables

21,408

21,062

Current tax liabilities

372

170

Contract liabilities

4,689

3,755

Provisions

473

87

Total current liabilities

31,988

28,022

Total liabilities

111,066

103,782

Net assets

11,606

24,416

Equity

Ordinary share capital issued

17

3,671

3,671

Share premium

7,359

7,359

Translation reserve

9,243

7,486

Retained earnings

(8,641)

5,926

Total equity attributable to equity holders of the Company

11,632

24,442

Non-controlling interests

(26)

(26)

Total equity

11,606

24,416

Approved by the Board of Directors and signed on its behalf by

Frank Doorenbosch

David Bedford

11 July 2023

 

11 July 2023

Consolidated statement of changes in equity for the year ended 31 March 2023

 

Attributable to equity holders of the Company

 

Share

 

Share

Translation

Retained

Non-controlling

Total

capital

 

premium

reserve

earnings

Total

interests

equity

 

 

 

£000

 

£000

£000

£000

£000

£000

£000

 

 

 

Balance at 1 April 2021

3,671

 

7,359

5,333

(8,426)

7,937

(26)

7,911

 

 

Profit for the year

-

 

-

-

5,799

5,799

-

5,799

 

 

Other comprehensive income / (expense):

 

 

Foreign exchange translation differences

-

 

-

1,840

-

1,840

-

1,840

Net investment hedge

-

 

-

440

-

440

-

440

Remeasurement gains on defined benefit scheme

-

 

-

-

8,480

8,480

-

8,480

Taxation on items above

-

 

-

(127)

-

(127)

-

(127)

 

 

Total comprehensive income for the period

-

 

-

2,153

14,279

16,432

-

16,432

 

 

Transactions with owners recorded directly in equity

 

 

 

 

Share-based payments

-

 

-

-

73

73

-

73

Taxation on items recorded directly in equity

-

 

-

-

-

-

-

-

 

 

Balance at 31 March 2022

3,671

 

7,359

7,486

5,926

24,442

(26)

24,416

Balance at 1 April 2022

3,671

 

7,359

7,486

5,926

24,442

(26)

24,416

Loss for the year

-

 

-

-

(3,957)

(3,957)

-

(3,957)

 

 

Other comprehensive income / (expense) income: 

 

 

Foreign exchange translation differences

-

 

-

1,129

-

1,129

-

1,129

Net investment hedge

-

 

-

818

-

818

-

818

Remeasurement losses on defined benefit scheme

-

 

-

-

(10,577)

(10,577)

-

(10,577)

Taxation on items above

-

 

-

(190)

-

(190)

-

(190)

 

 

Total comprehensive income / (expense) for the period

-

 

-

1,757

(14,534)

(12,777)

-

(12,777)

 

 

Transactions with owners recorded directly in equity:

 

 

 

 

Share-based payments

-

 

-

-

(33)

(33)

-

(33)

Taxation on items recorded directly in equity

-

 

-

-

-

-

-

-

 

 

Balance at 31 March 2023

3,671

 

7,359

9,243

(8,641)

11,632

(26)

11,606

Consolidated statement of cash flows

for the year ended 31 March 2023

FY22/23

FY21/22

 

 

Notes

£000

£000

Cash generated from operations

18

7,778

6,780

Interest paid

(2,955)

(2,502)

Tax paid

(1,051)

(1,309)

Net cash from operating activities

3,772

2,969

Cash flows from / (used in) investing activities

Proceeds from sale of business, net of cash disposed

-

693

Proceeds from sale of property, plant and equipment

1,390

20

Interest received

218

77

Purchase of property, plant and equipment

(2,313)

(4,804)

Purchase of intangible assets 

(104)

(135)

Net cash used in investing activities

(809)

(4,149)

Cash flows from / (used in) financing activities

Drawings on new and existing facilities

359

1,575

Refinancing costs

(250)

-

Proceeds from sale and leaseback of property, plant and equipment

1,222

1,410

Repayment of borrowings excluding lease liabilities

(1,800)

(2,282)

Repayment of other loan facilities

(102)

-

Repayment of lease liabilities 

(4,104)

(3,196)

Net cash used in financing activities

(4,675)

(2,493)

Net decrease in cash and cash equivalents

(1,712)

(3,673)

Cash and cash equivalents at beginning of period

12,347

15,485

Effect of exchange rate fluctuations on cash held

(281)

535

Cash and cash equivalents at end of period

10,354

12,347

Cash and cash equivalents comprise:

Cash and cash deposits

10,354

12,347

10,354

12,347

Notes on the preliminary statement

 

1 Basis of preparation

The financial statements included in this preliminary announcement have been prepared in accordance with the Disclosure and Transparency Rules of the UK Financial Conduct Authority, and the principles of UK-adopted international accounting standards, but do not comply with the full disclosure requirements of these standards. The financial information for the year ended 31 March 2022 is derived from the statutory financial statements for that year which have been delivered to the Registrar of Companies. The auditor reported on those financial statements: their report was unqualified, did not draw attention to any matters by way of emphasis and did not contain a statement under s498(2) or (3) of the Companies Act 2006. The financial information has been prepared on a going concern basis under the historic cost convention basis except that derivative financial instruments, share options

and defined benefit pension plan assets are stated at their fair value.

 

The unaudited financial information contained in this announcement does not constitute the statutory financial statements of the Group as at and for the year ended 31 March 2023, but is derived from those financial statements, which have been prepared in accordance with UK-adopted international accounting standards. The financial statements themselves will be approved by the Board of Directors and reported on by the auditor and then subsequently delivered to the Registrar of Companies. The Group expects to publish full consolidated statements on or around 28 July 2023. Accordingly, the financial information for FY22/23 is presented as unaudited in this announcement.

 

The financial statements are prepared on the going concern basis.

 

Group performance during the year has enabled capital investment to be made whilst retaining a stable financial position with net debt excluding lease liabilities as of 31 March 2023 increasing to £22.5 million (31 March 2022: £21.5 million).

 

Net debt including lease liabilities at 31 March 2023 was £34.4 million (31 March 2022: £32.4 million), with the principal reason behind the increase being foreign exchange movements of £1.5 million.

 

On 2 September 2022, the Group successfully refinanced with the Company's bank, concluding a first amendment and restatement agreement relating to the multi-currency term and revolving facilities agreement dated 14 August 2020. The debt facilities available to the Group at 31 March 2023 comprise a term loan of £29.3 million, of which £1.4 million will be amortised by 31 March 2024 and a further £2.2 million amortised by 31 March 2025. The balance becomes payable by the termination date, 30 June 2025.

At 31 March 2023, the term loans were denominated as follows: sterling 14.2 million, US dollar 13.3 million and euro 4.9 million. The facility also includes a £3.5 million revolving credit facility, denominated in sterling, maturing on 30 June 2025.

 

Since the year-end there have been no significant changes to the Group's liquidity position. The term loan balances stood at sterling 10.2 million, US dollar 13.3 million and euro 4.9 million, totalling £27.0 million on 30 June 2023, with undrawn facilities of £1.5 million on the RCF. 

As part of the original bank financing in August 2020 the Group became subject to four bank facility covenant tests. The quarterly covenants to be tested are:

Underlying interest cover;Net debt to underlying EBITDA;Core subsidiary underlying EBITA; andCore subsidiary revenue.

Core subsidiaries are defined as Carclo Technical Plastics Ltd; Bruntons Aero Products Ltd; Carclo Technical Plastics (Brno) s.r.o; CTP Carrera Inc and Jacottet Industrie SAS, with CTP Taicang Co. Ltd and Carclo Technical Plastics Pvt Co Ltd being treated as non-core for the purposes of these covenants.

Following a more than doubling of the base rate in the first half of FY22/23, the Group reassessed its forecasts and concluded there was insufficient headroom available to meet all the agreed banking covenants in the event of certain downside scenarios taking place. Breach of any of these covenants could lead to the creditors calling in their debt, leaving the plc insolvent. As a result, at the half year, in recognition of a potential covenant breach, the Group issued a material uncertainty warning over its ability to continue trading as a going concern. 

Since that time the Group has worked with the bank to amend the covenants and agreed adjustments to the Group’s interest cover covenant for both the December 2022 and March 2023 testing points. 

In December 2022 the Group announced the cancellation of a new business contract that would materially impact the results for FY22/23. Further discussions were held with the bank and, following a review of the Group’s 3-year plan up to March 2026, on 22 June the bank agreed to the Group’s request to further amend the interest cover covenant to June 2025 and to an adjustment to the net debt to underlying EBITDA covenant to December 2023.

The revised banking covenants and thresholds are assumed to be in place throughout the going concern assessment period. However, there remains a material uncertainty over going concern until the formal documentation is signed, which is expected to be completed before the publication of the Group’s Annual Report and Accounts.

 

A schedule of contributions is also in place with the pension trustees with an agreed £3.5 million to be paid annually until 31 October 2039. Additional contributions also agreed of 25% of any surplus of FY23/24 underlying EBITDA over £18 million payable from 30 June 2024 to 31 May 2025, extending to 26% of any FY24/25 surplus payable from 30 June 2025 to 31 May 2026.

In addition, the pension scheme has the benefit of a fifth covenant to be tested each year up to and including FY23. The test requires any shortfall of pension deficit recovery contributions when measured against Pension Protection Fund priority drift (which is a measure of the increase in the UK Pension Protection Fund's potential exposure to the Group's pension scheme liabilities), to be met by a combination of cash payments to the scheme, plus a notional (non-cash) proportion of the increase in the underlying value of the CTP and Aerospace segments based on an EBITDA multiple for those businesses which is determined annually. This test will be completed on the 31 March 2023 audited financial statements and management expect this covenant to be met.

 

The Group is subject to a number of key risks and uncertainties, as detailed in the Principal risks and uncertainties section in the Annual Report and Accounts. Mitigation actions are also considered in this section. These risks and uncertainties have been considered in the base case and severe downside sensitivities and have been modelled accordingly.

The Directors have reviewed cash flow and covenant forecasts to cover the period, at least twelve-months from the date of signing the consolidated financial statements, considering the Group's available debt facilities and the terms of the arrangements with the Group's bank and the Group pension scheme.

 

The base case forecast includes assumptions around sales, margins, working capital and interest rates. The sensitivity analysis has considered the risks facing the Group and has modelled the impact of each in turn, as well as considering the impact of aggregating certain risk types and shows that the Group is able to operate within its available facilities and meet its agreed covenants as they arise. Furthermore, the Directors have reviewed sensitivity testing, modelling a range of severe downside scenarios. These sensitivities attempt to incorporate identified risks set out in the Principal risks and uncertainties section of the Annual Report and Accounts.

Severe downside sensitivities modelled included a range of scenarios modelling the financial effects of loss of business from: discrete sites, an overall fall in gross margin of 1% across the Group, a fall in Group sales of 3% matched by a corresponding fall in cost of sales of the same amount and interest rate risk. 

The Group is not exposed to vulnerable sectors or vulnerable countries but does have certain key customers, which create risks and uncertainties. These risks and uncertainties are documented and the mitigating actions being taken are covered in detail in the Principal risks and uncertainties section in the Annual Report and Accounts.

 

On the basis of this forecast and sensitivity testing, the Board has determined that it is reasonable to assume that the Group will continue to operate within the facilities available and will be able to adhere to the covenant tests to which it is subject throughout at least the twelve-month period from the date of signing the financial statements. 

Accordingly, these financial statements are prepared on a going concern basis. 

Directors’ liability

 

Neither the Company nor the Directors accept any liability to any person in relation to this report except to the extent that such liability could arise under English law. Accordingly, any liability to a person who has demonstrated reliance on any untrue or mistaken statement or omission shall be determined in accordance with section 90(A) of the Financial Services and Markets Act 2000.

 

Responsibility statement of the Directors in respect of the annual report 

The Directors at the date of this statement confirm that to the best of their knowledge: 

the financial statements, prepared in accordance with the applicable set of accounting standards, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation taken as a whole; andthe strategic report includes a fair review of the development and performance of the business and the position of the issuer and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties that they face.

 

 

2 Accounting policies

The accounting policies set out in the last published financial statements for the year to 31 March 2022 have been applied consistently to all periods presented in this preliminary statement, unless otherwise stated. 

 

Judgements made by the Directors, in the application of these accounting policies that have significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed in note 3.

 

Certain new standards, amendments and interpretations to existing standards have been published that are mandatory for the Group’s accounting period beginning on or after 1 April 2022. The following new standards and amendments to standards are mandatory and have been adopted for the first time for the financial year beginning 1 April 2022:

IAS 16 Property, Plant and Equipment (Amendment): Proceeds before intended use (effective date 1 January 2022);IAS 37 Provisions, Contingent Liabilities and Contingent Assets (Amendment): Onerous contracts - Costs of Fulfilling a Contract (effective date 1 January 2022);IFRS 3 Business Combinations (Amendment): Reference to the Conceptual Framework (effective date 1 January 2022); andAnnual Improvements to IFRSs (2018-2020 cycle) (effective date 1 January 2022)

 

These standards have not had a material impact on the consolidated financial statements.

 

Certain new standards, amendments and interpretations to existing standards have been published that are mandatory for the Group’s accounting period beginning on or after 1 April 2023. The Group has elected not to early adopt these standards which are described below.

 

IAS 1 Presentation of Financial Statements (Amendment): Classification of liabilities as current or non-current, deferral of effective date and Exposure Draft: Non-current liabilities with covenants (effective date 1 January 2023, although the IASB has tentatively decided to defer the effective date further to being not before 1 January 2024); IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Material Judgements (Amendment): Disclosure of accounting policies (effective date 1 January 2023);IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors (Amendment): Definition of accounting estimates (effective date 1 January 2023); andIAS 12 Income Taxes: Deferred Tax related to assets and liabilities arising from a single transaction (effective 1 January 2023).

 

The above are not expected to have a material impact on the financial statements.

 

There are no other IFRS or IFRIC interpretations that are not yet effective that would be expected to have a material impact on the Group.

3 Accounting estimates and judgements

The preparation of the financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses.

The estimates and assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of revision and future periods if the revision affects both current and future periods.

The following are the critical judgements and key sources of estimation uncertainty that the Directors have made in the process of applying the Group’s accounting policies and that have the most significant effect on the amounts recognised in the financial statements. Management has discussed these with the Audit and Risk Committee. These should be read in conjunction with the significant accounting policies provided in the Annual Report and Accounts.

 

Going concern

Note 1 contains information about the preparation of these financial statements on a going concern basis.

 

Key judgements –

 

Management has exercised judgement over the likelihood of the Group being able to continue to operate within its available facilities and in accordance with its covenants for at least twelve months from the date of signing these financial statements. This determines whether the Group should operate the going concern basis of preparation for these financial statements.

 

Impairment of assets

Note 12 contains information about management's estimates of the recoverable amount of cash generating units and their risk factors.

 

Key judgements –

Management has exercised judgement over the underlying assumptions within the valuation models and has applied judgement to determine the Group's cash generating units to which goodwill is allocated and against which impairment testing is performed. These are key factors in their assessment of whether there is any impairment in related goodwill or other assets. Goodwill at 31 March 2023 amounts to £23.0 million (31 March 2022: £22.0 million)

Management have exercised judgement when considering if there have been indicators of impairment. Where indications exist, management have estimated recoverable amount as detailed below.

Key sources of estimation uncertainty –

The Group tests whether goodwill has suffered any impairment and considers whether there is any indication of impairment on an annual basis. As set out in more detail in notes 12 and 13, the recoverable amounts may be based on either value-in-use calculations or fair value less costs of disposal considerations. The former requires the estimation of future cash flows and the choice of a discount rate in order to calculate the present value of the future cash flows, the latter method requires the estimation of fair value.

Details of the sensitivity of assumptions is included in note 12.

Pension assumptions

Note 16 contains information about management's estimate of the net liability for defined benefit obligations and their risk factors. The pension liability at 31 March 2023 amounts to £34.5 million (31 March 2022: £26.0 million).

Key sources of estimation uncertainty –

The value of the defined benefit pension plan obligation is determined by long-term actuarial assumptions. These assumptions include discount rates, inflation rates and mortality rates. Differences arising from actual experience or future changes in assumptions will be reflected in the Group’s consolidated statement of comprehensive income. The Group exercises judgement in determining the assumptions to be adopted after discussion with a qualified actuary. Details of the key actuarial assumptions used and of the sensitivity of these assumptions are included within note 6.

In the prior year, the Scheme introduced a right for members to Pension Increase Exchange (PIE). Having taken actuarial advice, the Executive management exercised judgement that, similar to the Bridging Pension Option adopted in the year to 31 March 2021, 40% of members would take the PIE option at retirement. There is no change to either assumption in the current year. Any change in estimate would be recognised as remeasurement gains/(losses) through the consolidated statement of comprehensive income.

Lease break options

The Annual Report and Accounts contain information about lease break options.

Key judgement –

Management has applied judgement when determining the expected certainty that a break option within a lease will be exercised.

 

 

Revenue recognition

As revenue from design and engineering contracts is recognised over time, the amount of revenue recognised in a reporting period depends on the extent to which the performance obligations have been satisfied.

Key judgements –

The revenue recognised on certain contracts in the CTP segment required management to use judgement to apportion contract revenue to the design and engineering performance obligations.

Key sources of estimation uncertainty –

Revenue recognised on certain contracts in the CTP segment required management to estimate the remaining costs to complete the design and engineering performance obligation in order to determine the percentage of completion and revenue to recognise in respect of those performance obligations.

Recognition of deferred tax assets

Information about the deferred tax assets recognised in the consolidated statement of financial position is included in the Annual Report and Accounts.

Key judgement –

Management have exercised judgement over the level of future taxable profits in the UK against which to relieve the Group's deferred tax assets. On this basis management believe it is no longer appropriate to recognise deferred tax assets (other than a £0.3 million deferred tax asset which is available to off-set against a deferred tax liability of £0.3 million arising on historic property revaluations) and at 31 March 2023 UK deferred tax assets of £0.7 million have been derecognised (31 March 2022: £0.7 million recognised).

Classification of exceptional items

Note 6 contains information about items classified as exceptional.

Key judgements –

Management has exercised judgement over whether items are exceptional as set out in the Group's accounting policy.

Non-current assets classified as held for sale

Note 14 includes information about non-current assets held for sale.

Key judgements –

Management has applied judgement in determining whether a sale is highly probable at 31 March 2023 and as such whether non-current assets are classified as held for sale at the balance sheet date. Management have determined that these criteria did not apply to any non-current assets at 31 March 2023.

4 Segment reporting

The Group is organised into two, separately managed, business segments – CTP and Aerospace. These are the segments for which summarised management information is presented to the Group's chief operating decision maker (comprising the Main Board and Group Executive Committee).

The CTP segment supplies value-adding engineered solutions for the life science, optical and precision component industries. This business operates internationally in a fast growing and dynamic market underpinned by rapid technological development.

The Aerospace segment supplies systems to the manufacturing and aerospace industries.

The Central costs relate to the cost of running the Group, plc and non-trading companies.

The LED Technologies segment presented as a discontinued operation in the prior year was a leader in the development of high-power LED lighting for the premium automotive industry and was disposed of in the year to 31 March 2020. See note 5.

Transfer pricing between business segments is set on an arm’s length basis. Segmental revenues and results are after the elimination of transfers between business segments. Those transfers are eliminated on consolidation.

Analysis by business segment

The segment results for the year ended 31 March 2023 were as follows –

CTP

(continuing)

Aerospace

(continuing)

Central

(continuing)

Group total

 

 

 

 

 

 

 

 

 

 

 

£000

£000

£000

£000

 

 

 

 

 

 

 

 

 

 

Consolidated income statement

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External revenue

 

 

 

 

 

 

 

 

 

 

136,814

6,631

-

143,445

 

 

 

 

 

 

 

 

 

 

External expenses

 

 

 

 

 

 

 

 

 

 

(129,493)

(5,111)

(2,902)

(137,506)

 

 

 

 

 

 

 

 

 

 

Underlying operating profit / (loss)

 

 

 

 

 

 

 

 

 

 

7,321

1,520

(2,902)

5,939

 

 

 

 

 

 

 

 

 

 

Exceptional operating items

 

 

 

 

 

 

 

 

 

 

(2,752)

-

(1,958)

(4,710)

 

 

 

 

 

 

 

 

 

 

Operating profit / (loss)

 

 

 

 

 

 

 

 

 

 

4,569

1,520

(4,860)

1,229

 

 

 

 

 

 

 

 

 

 

Net finance expense

 

 

 

 

 

 

 

 

 

 

(3,749)

Income tax expense

 

 

 

 

 

 

 

 

 

 

(1,437)

 

 

 

 

 

 

 

 

 

 

Loss for the period

 

 

 

 

 

 

 

 

 

 

(3,957)

Consolidated statement of financial position

Segment assets

114,231

5,886

2,555

122,672

Segment liabilities

(40,000)

(1,198)

(69,868)

(111,066)

Net assets

74,231

4,688

(67,313)

11,606

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other segmental information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditure on property, plant and equipment

 

 

 

 

 

 

 

 

 

 

 

5,474

287

49

5,810

Capital expenditure on computer software

 

 

 

 

 

 

 

 

 

 

36

-

-

36

Capital expenditure on other intangibles

 

 

 

 

 

 

 

 

 

 

 

68

 

-

 

-

 

68

Depreciation

 

 

 

 

 

 

 

 

 

 

7,516

223

76

7,815

Impairment of property, plant and equipment

 

 

 

 

 

 

 

 

 

 

 

783

 

-

 

-

 

783

Amortisation of computer software

 

 

 

 

 

 

 

 

 

 

43

-

101

144

Amortisation of other intangibles

 

 

 

 

 

 

 

 

 

 

67

-

-

67

Impairment of intangible fixed assets

 

 

 

 

 

 

 

 

 

 

 

208

 

-

 

-

 

208

The segment results for the year ended 31 March 2022 were as follows –

 

 

CTP (continuing)

Aerospace

(continuing)

Central

(continuing)

Total

(continuing operations)

LED Technologies

(discontinued operations)

Group total

 

£000

£000

£000

£000

£000

£000

 

 

 

Consolidated income statement

External revenue

123,869

4,707

-

128,576

-

128,576

Expenses

(115,476)

(4,030)

(2,974)

(122,480)

-

(122,480)

Underlying operating profit / (loss)

8,393

677

(2,974)

6,096

-

6,096

Covid-19 related US government grant income

 

2,087

 

-

 

-

 

2,087

 

-

 

2,087

Operating profit / (loss) before exceptional items

 

10,480

 

677

 

(2,974)

 

8,183

 

-

 

8,183

Exceptional operating items

-

-

721

721

-

721

Operating profit / (loss)

10,480

677

(2,253)

8,904

-

8,904

Net finance expense

(2,989)

-

(2,989)

Income tax expense

(809)

-

(809)

Profit / (loss) from operating activities after tax

5,106

-

5,106

Profit on disposal of discontinued operations net of tax

 

 

 

 

 

 

 

-

 

693

 

693

Profit for the period

 

 

 

 

 

 

 

5,106

 

693

 

5,799

Consolidated statement of financial position

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment assets

121,119

6,418

661

128,198

-

128,198

Segment liabilities

(40,686)

(998)

(62,098)

(103,782)

-

(103,782)

Net assets

80,433

5,420

(61,437)

24,416

-

24,416

 

 

 

 

 

 

 

 

 

 

 

 

 

Other segmental information

 

 

 

 

Capital expenditure on property, plant and equipment

 

9,529

 

36

 

143

 

9,708

 

-

 

9,708

Capital expenditure on computer software

62

-

73

135

 

-

 

135

Depreciation

6,533

234

58

6,825

 

-

 

6,825

Amortisation of computer software

16

-

120

136

 

-

 

136

Amortisation of other intangibles

67

-

-

67

 

-

 

67

Analysis by geographical segment

 

The business operates in three main geographical regions - the United Kingdom, North America and in lower-cost regions including the Czech Republic, China and India. The geographical analysis was as follows: 

Expenditure on tangible and intangible fixed assets 

External revenue

Net segment (liabilities) / assets

FY22/23

FY21/22

FY22/23

FY21/22

FY22/23

FY21/22

£000

£000

£000

£000

£000

£000

United Kingdom

14,157

12,632

(40,329)

(29,367)

1,923

1,651

North America

70,955

65,296

27,909

27,267

3,204

6,918

Rest of world

58,333

50,648

24,026

26,516

787

1,274

143,445

128,576

11,606

24,416

5,914

9,843

The analysis of segment revenue represents revenue from external customers based upon the location of the customer.

The analysis of segment assets and capital expenditure is based upon the location of the assets.

The material components of the Central segment assets and liabilities are retirement benefit obligation net liabilities of £34.493 million (FY21/22: net liabilities of £25.979 million), and net borrowings of £31.250 million (FY21/22: £36.134 million).

One CTP customer accounted for 28.4% (FY21/22: 37.8%) and another customer for 10.5% (FY21/22:10.4%) of Group revenues from continuing operations and similar proportions of trade receivables.

 

No other customer accounted for more than 10.0% of revenues from continuing operations in the year.

Deferred tax assets by geographical location are as follows: United Kingdom £0.283 million (FY21/22: £0.952 million), North America £0.800 million (FY21/22: £0.288 million), rest of world £0.102 million (FY21/22: £0.163 million).

Total non-current assets by geographical location are as follows, United Kingdom £22.569 million (FY21/22: £24.159 million), North America £28.839 million (FY21/22: £28.142 million), rest of world £18.561 million (FY21/22: £18.895 million).

5 Discontinued operation

There were no new discontinued operations in the twelve months ended 31 March 2023 or in the prior year comparative. Prior year proceeds were in respect to amounts received from the administrators of Wipac Ltd which was part of the former LED Technologies segment, classified as discontinued in the year to 31 March 2020. Management does not expect to receive any further proceeds from the administrators of Wipac Ltd.

6 Exceptional items

FY22/23

FY21/22

£000

£000

Continuing operations

Rationalisation costs

(3,404)

(133)

Costs arising from cancellation of future supply agreement

(877)

-

Doubtful debt and related inventory provision

(896)

-

Costs in respect of legacy claims

(302)

-

Credit arising on the disposal of surplus properties

769

-

Past service credit in respect of retirement benefits

-

854

(4,710)

721

Discontinued operations

Profit on disposal of discontinued operations

-

693

-

693

(4,710)

1,414

Rationalisation costs from continuing operations during the period relate to the restructuring and refinancing of the Group. These include £1.4 million employee and other related costs in respect to restructuring of the Central and CTP divisions, £1.0 million impairment costs relating to manufacturing footprint rationalisation (inventory £0.4 million, fixed assets £0.3 million, intangible assets £0.2 million and an onerous lease provision £0.2 million), £0.7 million legal and professional costs relating to refinancing and £0.2 million exceptional pension scheme administration costs incurred to ensure successful refinancing with the Group's principal bank and Group pension scheme. Prior year costs were £0.2 million exceptional pension scheme administration costs, £0.1 million consultant fees and a £0.1million credit being the release of accruals in respect to legal and professional costs.

On 30 May 2023, the Group signed a full and final settlement agreement with a leading global OEM customer. Due to a contraction in the end-market demand for COVID testing, they would not be proceeding into the production phase of the project, see note 19. Receiving notice in December 2022 was deemed by management to be an event that might be an indicator of impairment at 31 March 2023. An impairment review was undertaken, with final settlement providing evidence that impairment existed. As a result, the Group has recognised a £0.9 million impairment for: a £0.3 million inventory provision, £0.5 million fixed asset impairment and £0.1 million other costs in the income statement in the year to 31 March 2023. The Group expects to recognise an exceptional gain in the income statement to 31 March 2024 of approximately £0.6 million.

 

In March 2023, a customer of the CTP division, in the USA, provided notice that it would be ceasing to operate. £0.6 million provision has been made for the debt outstanding at year end less any amounts expected to be recovered through credit insurance, and a £0.3 million provision for inventory purchased specifically for that customer. 

 

A provision has been recognised in the current year for £0.3 million (2022: £nil), in respect to health-related legacy claims.

The credit arising on the disposal of surplus properties in the year is the profit arising on the sale and leaseback arrangement of the CTP manufacturing site at Tucson, Arizona, USA, see note 14.

 

The gain in respect to retirement benefits in the prior year is a past service credit for the impact of introducing a Pension Increase Exchange option to members. See note 16 for more information.

The prior period profit on disposal of discontinued operations of £0.7 million was proceeds received in that year from the administrators of Wipac Limited. See note 5.

 

 

7 Government support for Covid-19

In April 2020, the Group received a loan under the Paycheck Protection Program, underwritten by the US government in support of Covid-19 for $2.9 million. On 5 May 2021, notice of forgiveness of the loan was received from the Small Business Administration, resulting in its conversion from a loan to a grant and therefore its release to the consolidated income statement.

The credit recognised in respect to the Covid-19 related government grant was presented separately on the face of the consolidated income statement for the year ended 31 March 2022 for clarity.

8 Net Finance expense

 

FY22/23

FY21/22

 

 

 

 

 

 

 

 

 

 

£000 

£000 

The expense recognised in the consolidated income statement comprises:

Interest receivable on cash and cash deposits

218

77

Interest payable on bank loans and overdrafts

(2,569)

(1,794)

Lease interest

(674)

(527)

Other interest

(59)

(18)

Interest on the net defined benefit pension liability

(665)

(727)

Finance expense

(3,749)

(2,989)

 

 

9 Income tax expense

The expense recognised in the consolidated income statement comprises-

FY22/23

FY21/22

£000

£000

United Kingdom corporation tax

Adjustments for prior years

(18)

(14)

 

 

 

Overseas taxation:

Current tax

(1,462)

(1,266)

Adjustments for prior years

110

(190)

 

 

 

Total current tax net expense

(1,370)

(1,470)

 

 

Deferred tax expense

Origination and reversal of temporary differences:

Deferred tax

(20)

629

Adjustments for prior years

17

32

Rate Change

(64)

-

Total deferred tax (charge) / credit

(67)

661

Total income tax expense recognised in the consolidated income statement

(1,437)

(809)

 

 

Reconciliation of tax expense for the year –

 

The Group has reported an effective tax rate for the period of (57.0%) which is significantly below the standard rate of UK corporation tax of 19%. The differences are explained as follows –

FY22/23

FY21/22

£000

%

£000

%

(Loss) / Profit before tax

(2,520)

6,608

Income tax using standard rate of UK corporation tax of 19% (FY21/22: 19%)

(479)

19.0

1,256

19.0

Expenses not deductible for tax purposes

128

(5.1)

267

4.0

R&D tax relief

-

 

-

(22)

(0.3)

Income not taxable

(125)

5.0

(603)

(9.1)

Adjustments in respect of overseas tax rates

155

(6.2)

273

4.1

Derecognition / (Recognition) of deferred tax asset previously recognised / unrecognised

669

 

(26.5)

(657)

(9.9)

Unprovided deferred tax movement

982

(39.0)

(412)

(6.2)

Adjustment to current tax in respect of prior periods (UK and overseas)

(92)

3.7

204

3.1

Adjustments to deferred tax in respect of prior periods (UK and overseas)

(17)

(0.7)

(32)

(0.5)

Foreign taxes expensed in the UK

210

(8.3)

535

8.1

Rate change on deferred tax

64

 

(2.5)

-

-

Foreign exchange currency loss

(58)

 

2.3

-

-

 

 

 

 

 

 

Total income tax expense

1,437

(57.0)

809

12.2

 

Tax on items charged outside of the consolidated income statement –

 

FY22/23

FY21/22

£000

£000

Recognised in other comprehensive income:

 

 

 

 

Foreign exchange movements

190

127

 

 

 

 

Total income tax charged to other comprehensive income

190

127

10 (Loss) / earnings per share

 

The calculation of basic earnings per share is based on the (loss) / profit attributable to equity holders of the parent company divided by the weighted average number of ordinary shares outstanding during the year.

The calculation of diluted earnings per share is based on the (loss) / profit attributable to equity holders of the parent company divided by the weighted average number of ordinary shares outstanding during the year (adjusted for dilutive options).

The following details the result and average number of shares used in calculating the basic and diluted earnings per share –

FY22/23

FY21/22

£000

£000

(Loss) / profit after tax but before profit on discontinued operations

(3,957)

5,106

(Loss) / profit attributable to non-controlling interests

-

-

(Loss) / profit attributable to ordinary shareholders from continuing operations

(3,957)

5,106

Profit on discontinued operations, net of tax

-

693

(Loss) / profit after tax, attributable to equity holders of the parent

(3,957)

5,799

 

FY22/23

FY21/22

Shares

Shares

Weighted average number of ordinary shares in the year

73,419,193

73,419,193

Effect of share options in issue

15,974

324,977

Weighted average number of ordinary shares (diluted) in the year

73,435,167

73,744,170

 

None of the awards outstanding under the performance share plan are expected to vest at 31 March 2023. As these potential ordinary shares are anti-dilutive at 31 March 2023, they have not been included in the calculation of dilutive earnings per share.

 

In addition to the above, the Company also calculates an earnings per share based on underlying profit as the Board believes this provides a more useful comparison of business trends and performance. Underlying profit is defined as profit before impairments, rationalisation costs, one-off retirement benefit effects, exceptional bad debts, business closure costs, litigation costs, other separately disclosed one-off items and the impact of property and business disposals, net of attributable taxes.

The following table reconciles the Group's (loss) / profit to underlying profit used in the numerator in calculating underlying earnings per share:

FY22/23

FY21/22

£000

£000

 

 

 

(Loss) / profit after tax, attributable to equity holders of the parent

(3,957)

5,799

 

 

 

Continuing operations:

Exceptional – rationalisation and restructuring costs, net of tax

3,070

133

Exceptional – Costs arising from cancellation of future supply agreement, net of tax

752

-

Exceptional – Doubtful debt and related inventory provision, net of tax

673

-

Exceptional – Costs in respect to legacy claims, net of tax

302

-

Exceptional – Credit arising on the disposal of surplus properties, net of tax

(578)

-

Exceptional – gain in respect of retirement benefits, net of tax

-

(854)

Covid-19-related US government grant income, net of tax

-

(2,087)

 

 

 

Discontinued operations:

Exceptional – Gain on disposal of discontinued operations, net of tax

-

(693)

 

 

 

Underlying profit attributable to equity holders of the parent

262

2,298

 

Covid-19-related US government grant income, net of tax

-

 

2,087

 

 

 

Profit after tax but before exceptional items, attributable to equity holders of the parent

262

 

4,385

Underlying operating profit – continuing operations

5,939

6,096

Finance revenue – continuing operations

218

77

Finance expense – continuing operations

(3,967)

(3,066)

Income tax expense – continuing operations

(1,928)

(809)

Underlying profit attributable to equity holders of the parent – continuing operations

262

2,298

 

 

 

 

Covid-19-related US government grant income, net of tax

-

 

2,087

 

 

 

 

Profit after tax but before exceptional items – continuing operations

262

 

4,385

 

 

The following table summarises the earnings per share figures based on the above data –

 

FY22/23

FY21/22

Pence

Pence

Basic (loss) / earnings per share – continuing operations

(5.4)

7.0

Basic (loss) / earnings per share – discontinued operations

-

0.9

Basic (loss) /earnings per share

(5.4)

7.9

Diluted (loss) / earnings per share – continuing operations

(5.4)

6.9

Diluted (loss) / earnings per share – discontinued operations

-

0.9

Diluted (loss) / earnings per share

(5.4)

7.9

Underlying earnings per share – basic – continuing operations

0.4

3.1

Underlying earnings per share – basic – discontinued operations

-

-

Underlying earnings per share – basic

0.4

3.1

Underlying earnings per share – diluted – continuing operations

0.4

3.1

Underlying earnings per share – diluted – discontinued operations

-

-

Underlying earnings per share – diluted

0.4

3.1

Earnings per share before exceptional items – basic – continuing operations

0.4

 

6.0

Earnings per share before exceptional items – basic – discontinued operations

-

 

-

Earnings per share before exceptional items – basic

0.4

 

6.0

Earnings per share before exceptional items – diluted – continuing operations

0.4

 

6.0

Earnings per share before exceptional items – diluted – discontinued operations

-

 

-

Earnings per share before exceptional items – diluted

0.4

 

6.0

 

 

 

 

 

 

11 Dividends paid and proposed

 

The Directors are not proposing a final dividend for the year ended 31 March 2023 (31 March 2022: £nil). Under the terms of the amended and restated bank facilities agreement, the Group is not permitted to make a dividend payment to shareholders up to the period ending June 2025.

 

 

 

12 Intangible assets

 

 

 

 

Patents and

 

Customer-

 

 

 

 

 

development 

 

related

Computer

 

 

 

Goodwill

 

costs

 

intangibles

Software

 

Total

 

£’000

 

£’000

 

£000

£000

 

£000

 

 

 

 

 

 

 

Cost

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 31 March 2021

22,408

 

16,734

 

527

1,741

 

41,410

 

 

 

 

 

 

 

 

 

Additions

-

 

-

 

-

135

 

135

Effect of movements in foreign exchange

 

686

 

 

-

 

26

 

23

 

735

 

 

 

 

 

 

 

 

 

Balance at 31 March 2022

23,094

 

16,734

 

553

1,899

 

42,280

 

 

 

 

 

 

 

 

 

Additions

-

 

68

 

-

36

 

104

Disposals

-

 

-

 

-

(14)

 

(14)

Effect of movements in foreign exchange

 

1,005

 

 

-

 

35

 

31 

 

1,071 

 

 

 

 

 

 

 

 

 

Balance at 31 March 2023

24,099

 

16,802

 

588

1,952 

 

43,441 

 

 

 

 

 

 

 

 

 

Amortisation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at 31 March 2021

1,343

 

16,734

 

235

1,250

 

19,562

 

 

 

 

 

 

 

 

 

Amortisation for the year

-

 

-

 

67

136

 

203 

Effect of movements in foreign exchange

 

(213)

 

 

-

 

-

 

14

 

(199) 

 

 

 

 

 

 

 

 

 

Balance at 31 March 2022

1,130

 

16,734

 

302

1,400

 

19,566

 

 

 

 

 

 

 

 

 

Amortisation for the year

-

 

6

 

61

144

 

211

Impairment

-

 

-

 

208

-

 

208 

Effect of movements in foreign exchange

 

(41)

 

 

-

 

17

 

17

 

(7)

 

 

 

 

 

 

 

 

 

Balance at 31 March 2023

1,089

 

16,740

 

588

1,561

 

19,978

 

 

 

 

 

 

 

 

 

Carrying amounts

 

 

 

 

 

 

 

 

At 1 April 2021

21,065

 

-

 

292

491

 

21,848

At 31 March 2022

21,964

 

-

 

251

499 

 

22,714 

At 31 March 2023

23,010

 

62

 

-

391 

 

23,463 

 

 

 

 

 

 

 

 

 

 

The Group has incurred research and development costs of £0.2 million (FY21/22: £0.2 million) which have been included within operating expenses in the consolidated income statement.

The decision by the Directors of the Group to proceed with a plan of rationalisation of the USA manufacturing footprint led to an impairment review of certain of the site assets. A customer-related intangible asset which was recognised on acquisition of one of the USA sites was reviewed as part of this exercise, and as the Group now has minimal trading with the customers to which it related, the carrying amount has been fully impaired and recognised as an exceptional item, see note 6.

 

Impairment tests for cash generating units containing goodwill

 

Goodwill acquired in a business combination is allocated at acquisition to the cash generating units (“CGUs”) that are expected to benefit from that business combination. The carrying amount of goodwill is allocated to the Group’s principal CGUs, being the operating segments described in the operating segment descriptions in note 4. 

The carrying value of goodwill at 31 March 2023 and 31 March 2022 is allocated wholly to the CTP cash generating unit as follows:

FY22/23

FY21/22

£000

£000

CTP

23,010

21,964

At 31 March 2023, the recoverable amount of the CTP cash generating unit was determined on a calculation of value in use, being the higher of that and fair value less costs of disposal “FVLCD”. The results of each produced the same answer, that there is no impairment of goodwill.

The value in use calculations use cash flow projections based upon financial budgets approved by management covering a three-year period. Cash flows beyond the three-year period are extrapolated using estimated growth rates of between 2.0% and 4.1% (FY21/22: 2.3% and 4.2%) depending upon the market served. 

 

The cash flows were discounted at pre-tax rates in the range 9.3% - 10.4% (FY21/22: 6.1% - 8.7%). These rates are calculated and reviewed annually and are based on the Group’s weighted average cost of capital. Changes in income and expenditure are based on expectations of future changes in the market. Sensitivity testing of the recoverable amount to reasonably possible changes in key assumptions has been performed, including changes in the discount rate and changes in forecast cash flows.

All other assumptions unchanged, a 5.5% (FY21/22: 6.6%) increase in the discount rate increasing the range to 14.8% - 15.9% (FY21/22: 12.7% - 15.3%), or a 28.8% (FY21/22: 45.0%) decrease in underlying EBIT would reduce the headroom on the CTP CGU to £nil. Should the discount rate increase further than this or the profitability decrease further, then an impairment of the goodwill would be likely.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

13 Property, plant and equipment

 

Land and

Plant and

 

 

buildings

equipment

 

Total

£000

£000

 

£000

 

 

Cost

 

 

 

 

Balance at 31 March 2021

36,446 

67,659

 

104,105

 

 

 

 

 

Additions

5,792

3,916

 

9,708

Disposals

(3)

(1,087)

 

(1,090)

Reclassification to assets held for sale

(608)

-

 

(608)

Effect of movements in foreign exchange

1,296

1,639

 

2,935

 

 

 

 

 

Balance at 31 March 2022

42,923

72,127

 

115,050

 

 

 

 

 

Additions

1,662

4,148

 

5,810

Disposals

-

(1,483)

 

(1,483)

Reclassification to assets held for sale

(153)

-

 

(153)

Effect of movements in foreign exchange

1,709

1,840

 

3,549

 

 

 

 

 

Balance at 31 March 2023

46,141

76,632

 

122,773

 

 

 

 

 

Depreciation and impairment losses

 

 

 

 

Balance at 31 March 2021

12,848

48,039

 

60,887

Depreciation charge for the year

3,338

3,487

 

6,825

Disposals

(2)

(1,068)

 

(1,070)

Reclassification to assets held for sale

(342)

-

 

(342)

Effect of movements in foreign exchange

621

1,165

 

1,786

 

 

 

 

 

Balance at 31 March 2022

16,463

51,623

 

68,086

 

 

 

 

 

Depreciation charge for the year

3,596

4,219

 

7,815

Disposals

-

(999)

 

(999)

Reclassification to assets held for sale

(89)

-

 

(89)

Impairment

-

783

 

783

Effect of movements in foreign exchange

704

1,152

 

1,856

 

 

 

 

 

Balance at 31 March 2023

20,674

56,778

 

77,452

 

 

 

 

 

Carrying amounts

 

 

 

 

At 1 April 2021

23,598 

19,620

 

43,218 

At 31 March 2022

26,460

20,504

 

46,964

At 31 March 2023

25,467

19,854

 

45,321

 

At 31 March 2023, properties with a carrying amount of £2.6 million were subject to a registered charge in favour of the Group pension scheme (FY21/22: £2.7 million) capped at £5.1 million.

 

Property, plant and equipment includes right-of-use assets.

A further £0.1 million net carrying value was reclassified from land and buildings to assets held for sale as set out in note 14 (FY21/22: £0.3 million).

Receiving notice from a leading global OEM CTP customer in December 2022 that they would not be proceeding into the production phase of a project was deemed by management to be an event that might be an indicator of impairment at 31 March 2023. An impairment review was undertaken, with final settlement providing evidence that impairment existed. The Directors have undertaken an exercise to determine the recoverable amount of assets that were earmarked for use on this project where recoverable amount is the higher of value in use and fair value less costs of disposal. Whilst the significant proportion of fixed assets at 31 March 2023 will be repurposed within the business, there are a number of machines which management have decided to sell. As a result, an impairment charge of £0.485 million has been recognised in the year ended 31 March 2023 and has been disclosed as an exceptional item in the consolidated income statement, see note 6, being the difference between NBV at year end and fair value less costs of disposal.

 

 

The decision by the Directors of the Group to proceed with a plan of rationalisation of the CTP USA manufacturing footprint, led to an impairment review of the site’s assets. Whilst a number of the assets will be repurposed within the Group and are supported by the value in use calculations of the CTP division, there are a number of assets that have been identified that will be disposed of. These assets have been impaired to fair value less costs to dispose, resulting in an impairment charge of £0.299 million, recognised as an exceptional item, see note 6.

Refer to note 12 for details of cash flows and assumptions used in value in use calculations.

14 Non-current assets classified as held for sale

FY22/23

FY21/22

£000

£000

 

 

 

Land and buildings held for sale at 1 April

266

-

Additions

64

266

Effect of movements in foreign exchange

30

-

Disposals

(360)

-

 

 

 

Net assets held for sale at 31 March

-

266

 

 

 

 

On 11 July 2022, the Group finalised a sale and leaseback arrangement of a CTP manufacturing site at Tucson, Arizona, USA for agreed consideration of $2.95 million less costs of $0.155 million (£2.351 million net). A lease term of eight years and four months was agreed and grants the Group the right to cancel any time after 1 October 2025, provided twelve months’ notice is given. At 31 March 2023 there is no reasonable certainty that the Group will exercise the break clause.

 

The total net book value of the property amounted to £0.7 million at the date of disposal, however only the proportion relating to the disposed useful economic life was classified as held for sale (£0.4 million) prior to disposal. The balance of £0.4 million that relates to the right of use asset remained in owned property, plant and equipment until completion, when it was transferred into right-of-use assets. The profit on the portion relating to the disposed useful economic life amounted to £0.8 million and has been classified as exceptional income in the consolidated income statement.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

15 Loans and borrowings

 

 

Reconciliation of movements of liabilities to cash flows arising from financing activities:

 

 

Term loan

£000

Government Covid-19 support loan

£000

Revolving credit facility

£000

Lease liabilities

£000

Other loans

£000

Total

£000

Balance at 31 March 2021

31,812

2,104

2,000

7,055

110

43,081

Changes from financing cashflows

 

 

 

 

 

 

Drawings on new facilities

-

-

1,500

-

75

1,575

Repayment of borrowings

(2,218)

-

-

(3,195)

(64)

(5,477)

 

(2,218)

-

1,500

(3,195)

11

(3,902)

Effect of changes in foreign exchange rates

440

(17)

-

192

1

616

Liability-related other charges

 

 

 

 

 

 

Drawings on new facilities

-

-

-

6,818

-

6,818

Conversion of loan to a grant

-

(2,087)

-

-

-

(2,087)

Interest expense

226

-

-

-

-

226

 

226

(2,087)

-

6,818

-

4,957

Equity-related other changes

-

-

-

-

-

-

Balance at 31 March 2022

30,260

-

3,500

10,870

122

44,752

Changes from financing cashflows

 

 

 

 

 

 

Drawings on new facilities

-

-

-

-

359

359

Transaction costs associated with the issue of debt

(500)

-

-

-

-

(500)

Repayment of borrowings

(1,800)

-

-

(4,328)

(102)

(6,230)

 

(2,300)

-

-

(4,328)

257

(6,371)

Effect of changes in foreign exchange rates

818

-

-

373

15

1,206

Liability-related other changes

 

 

 

 

 

 

Drawings on new facilities

-

-

-

4,955

-

4,955

Interest expense- presented within exceptional items

69

-

-

-

-

69

Interest expense – presented within finance expense

103

-

-

-

-

103

 

172

-

-

4,955

-

5,127

Equity-related other changes

-

-

-

-

-

-

Balance at 31 March 2023

28,950

-

3,500

11,870

394

44,714

 

 

 

 

 

 

 

 

 

16 Retirement benefit obligations

The Group operates a defined benefit UK pension scheme which provides pensions based on service and final pay. Outside of the UK, retirement benefits are determined according to local practice and funded accordingly.

In the UK, Carclo plc sponsors the Carclo Group Pension Scheme (the “Scheme”), a funded defined benefit pension scheme which provides defined benefits for some of its members. This is a legally separate, trustee-administered fund holding the Scheme’s assets to meet long-term pension liabilities for some 2,561 current and past employees as at 31 March 2023.

The trustees of the Scheme are required to act in the best interest of the Scheme’s beneficiaries. The appointment of the trustees is determined by the Scheme’s trust documentation. It is policy that one-third of all trustees should be nominated by the members. The trustees currently comprise two Company-nominated trustees (of which one is an independent professional trustee, and one is the independent professional Chairperson) as well as two member-nominated trustees. The trustees are also responsible for the investment of the Scheme’s assets.

The Scheme provides pensions and lump sums to members on retirement and to their dependants on death. The level of retirement benefit is principally based on final pensionable salary prior to leaving active service and is linked to changes in inflation up to retirement. The defined benefit section is closed to new entrants who now have the option of entering the defined contribution section of the Scheme, and the Group has elected to cease future accrual for existing members of the defined benefit section such that members who have not yet retired are entitled to a deferred pension.

 

The Company currently pays contributions to the Scheme as determined by regular actuarial valuations. The trustees are required to use prudent assumptions to value the liabilities and costs of the Scheme whereas the accounting assumptions must be best estimates.

The Scheme is subject to the funding legislation, which came into force on 30 December 2005, outlined in the Pensions Act 2004. This, together with documents issued by the Pensions Regulator and Guidance Notes adopted by the Financial Reporting Council, set out the framework for funding defined benefit occupational pension plans in the UK.

A full actuarial valuation was carried out as at 31 March 2021 in accordance with the scheme funding requirements of the Pensions Act 2004. The funding of the Scheme is agreed between the Group and the trustees in line with those requirements. These, in particular, require the surplus or deficit to be calculated using prudent, as opposed to best estimate, actuarial assumptions. The 31 March 2021 actuarial valuation showed a deficit of £82.8 million. Under the recovery plan agreed with the trustees following the 2021 valuation, the Group agreed that it would aim to eliminate the deficit, over a period of 18 years and 7 months starting from the valuation date and continuing until 31 October 2039, by the payment of annual contributions combined with the assumed asset returns in excess of gilt yields. Contributions paid in respect of the year to 31 March 2022 amounted to £3.9 million, £3.85 million in respect of the year to 31 March 2023 and are agreed as £3.5 million annually thereafter, plus additional contributions of 25% of any surplus of FY23/24 underlying EBITDA over £18.0 million payable from 30 June 2024 to 31 May 2025, extending to 26% of any FY24/25 surplus payable from 30 June 2025 to 31 May 2026. These contributions include an allowance in respect of the expenses of running the Scheme and the Pension Protection Fund (“PPF”) levy of £1.2 million in the year to 31 March 2022, £0.85 million in years ending 31 March 2023, 2024 and 2025 and £0.6 million in the year to 31 March 2026 and beyond.

At each triennial valuation, the schedule of contributions is reviewed and reconsidered between the employer and the trustees; the next review being no later than by 31 July 2025 after the results of the 31 March 2024 triennial valuation are known.

On 14 August 2020 additional security was granted by certain Group companies to the Scheme trustees such that at 31 March 2023 the gross value of the assets secured, which includes applicable intra-group balances, goodwill and investments in subsidiaries at net book value in the relevant component companies’ accounts, but which eliminate in the Group upon consolidation, amounted to £251.5 million (31 March 2022: £248.2 million). Excluding the assets which eliminate in the Group upon consolidation the value of the security was £38.0 million (31 March 2022: £36.3 million).

For the purposes of IAS 19, the results of the actuarial valuation as at 31 March 2021, which was carried out by a qualified independent actuary, have been updated on an approximate basis to 31 March 2023. There have been no changes in the valuation methodology adopted for this period’s disclosures compared to the previous period’s disclosures.

The Scheme exposes the Group to actuarial risks and the key risks are set out in the table below. In each instance these risks would detrimentally impact the Group’s statement of financial position and may give rise to increased interest costs in the Group income statement. The trustees could require higher cash contributions or additional security from the Group.

 

The trustees manage governance and operational risks through a number of internal controls policies, including a risk register and integrated risk management. 

Risk

Description

Mitigation

Investment risk

Weaker than expected investment returns result in a worsening in the Scheme’s funding position.

The trustees continually monitor investment risk and performance and have established an investment sub-committee which includes a Group representative, meets regularly and is advised by professional investment advisors. A number of the investment managers operate tactical investment management of the plan assets.

 

The Scheme currently invests approximately 69% of its asset value in liability-driven investments, 28% in a portfolio of diversified growth funds and 3% in cash and liquidity funds. The objective of the growth portfolio is that in combination, the matching credit, liability-driven investments and cash components generate sufficient return to meet the overall portfolio return objective.

Interest rate risk

A decrease in corporate bond yields increases the present value of the IAS 19 defined benefit obligations.

 

A decrease in gilt yields results in a worsening in the Scheme’s funding position.

The trustees’ investment strategy includes investing in liability-driven investments and bonds whose values increase with decreases in interest rates. 

 

Approximately 105% of the Scheme’s funded liabilities are currently hedged against interest rates using liability-driven investments.

 

It should be noted that the Scheme hedges interest rate risk on a statutory and long-term funding basis (gilts) whereas AA corporate bonds are implicit in the IAS 19 discount rate and so there is some mismatching risk to the Group should yields on gilts and corporate bonds diverge.

Inflation risk

An increase in inflation results in higher benefit increases for members which in turn increases the Scheme’s liabilities.

The trustees' investment strategy includes investing in liability-driven investments which will move with inflation expectations with approximately 110% of the Scheme’s inflation-linked liabilities being hedged on a funded basis. The growth assets held are expected to provide protection over inflation in the long term.

Mortality risk

An increase in life expectancy leads to benefits being payable for a longer period which results in an increase in the Scheme’s liabilities.

The trustees' actuary provides regular updates on mortality, based on scheme experience, and the assumption continues to be reviewed.

The amounts recognised in the statement of financial position in respect of the defined benefit scheme were as follows:

FY22/23

FY21/22

£000

£000

Present value of funded obligations

(134,091)

(181,759)

Fair value of scheme assets

99,598

155,780

Recognised liability for defined benefit obligations

(34,493)

(25,979)

The present value of Scheme liabilities is measured by discounting the best estimate of future cash flows to be paid out of the Scheme using the projected unit credit method. The value calculated in this way is reflected in the net liability in the statement of financial position as shown above.

The projected unit credit method is an accrued benefits valuation method in which allowance is made for projected earnings increases. The accumulated benefit obligation is an alternative actuarial measure of the Scheme’s liabilities whose calculation differs from that under the projected unit credit method in that it includes no assumption for future earnings increases. In this case, as the Scheme is closed to future accrual, the accumulated benefit obligation is equal to the valuation using the projected unit credit method.

All actuarial remeasurement gains and losses will be recognised in the year in which they occur in other comprehensive income.

The cumulative remeasurement net loss reported in the statement of comprehensive income since 1 April 2004 is £51.433 million.

IFRIC 14 has no effect on the figures disclosed because the Company has an unconditional right to a refund under the resulting trust principle.

Movements in the net liability for defined benefit obligations recognised in the consolidated statement of financial position:

FY22/23

FY21/22

£000

£000

Net liability for defined benefit obligations at the start of the year

(25,979)

(37,275)

Contributions paid

4,142

3,900

Net expense recognised in the consolidated income statement (see below)

(2,079)

(1,084)

Remeasurement (losses) / gains recognised in other comprehensive income

(10,577)

8,480

Net liability for defined benefit obligations at the end of the year

(34,493)

(25,979)

Movements in the present value of defined benefit obligations:

 

FY22/23

FY21/22

£000

£000

Defined benefit obligation at the start of the year

181,759

204,654

Interest expense

4,750

3,986

Actuarial loss due to scheme experience

4,897

 

-

Actuarial gains due to changes in demographic assumptions

(7,539)

(1,767)

Actuarial gains due to changes in financial assumptions

(38,032)

(13,476)

Benefits paid

(11,744)

(10,784)

Past service credit (see note 6)

-

(854)

Defined benefit obligation at the end of the year

134,091

181,759

There have been no plan amendments, curtailments, or settlements during the period.

In the prior year, the scheme introduced a Pension Increase Exchange (“PIE”). A Deed of Amendment, signed 16 March 2022, created the right for deferred members to take PIE at retirement. It also created the right for members to receive PIE on terms such that 20% of the PIE value is retained within the Scheme. Based upon the assumption that 40% of members will opt for PIE at retirement, this resulted in a reduction in the value of accrued liabilities and as a result a past service credit was recognised in the income statement of £0.9 million in that year, presented within exceptional items.

The English High Court ruling in Lloyds Banking Group Pension Trustees Limited v Lloyds Bank plc and others was published on 26 October 2018, and held that UK pension schemes with Guaranteed Minimum Pensions (“GMPs”) accrued from 17 May 1990 must equalise for the different effects of these GMPs between men and women. The case also gave some guidance on related matters, including the methods for equalisation.

The trustees of the plan will need to obtain legal advice covering the impact of the ruling on the plan, before deciding with the employer on the method to adopt. The legal advice will need to consider (amongst other things) the appropriate GMP equalisation solution, whether there should be a time limit on the obligation to make back-payments to members (the “look-back” period) and the treatment of former members (members who have died without a spouse and members who have transferred out for example).

In the year to 31 March 2020 the trustees commissioned scheme-specific calculations to determine the likely impact of the ruling on the Scheme. An allowance for the impact of GMP equalisation was included within the accounting figures for that year, increasing liabilities by 1.68%, thereby resulting past service cost of £3.6 million was recognised in the income statement at that time. The Scheme has not yet implemented GMP equalisation and therefore the allowance made in 2019 has been maintained for accounting disclosures.

On 20 November 2020, the High Court issued a supplementary ruling in the Lloyds Bank GMP equalisation case with respect to members that have transferred out of their scheme prior to the ruling. The results mean that trustees are obliged to make top-up payments that reflect equalisation benefits and to make top-up payments where this was not the case in the past. Also, a defined benefit scheme that received a transfer is concurrently obliged to provide equalised benefits in respect to the transfer payments and, finally, there were no exclusions on the grounds of discharge forms, CETV legislation, forfeiture provisions or the Limitation Act 1980.

The impact of this ruling was estimated to cost £0.2 million (approximately 0.1% of liabilities). This additional service cost was recognised through the income statement as a past service cost in the year ending 31 March 2021 and was presented within exceptional items and therefore the impact of the ruling is allowed for in the figures presented at 31 March 2023.

The Scheme’s liabilities are split between active, deferred and pensioner members at 31 March as follows:

FY22/23

FY21/22

%

%

Active 

-

-

Deferred

29

35

Pensioners

71

65

100

100

Movements in the fair value of Scheme assets:

FY22/23

FY21/22

£000

£000

Fair value of Scheme assets at the start of the year

155,780

167,379

Interest income

4,085

3,259

Loss on Scheme assets excluding interest income

(51,251)

(6,763)

Contributions by employer

4,142

3,900

Benefits paid

(11,744)

(10,784)

Expenses paid

(1,414)

(1,211)

Fair value of Scheme assets at the end of the year

99,598

155,780

 

 

 

 

Actual loss on Scheme assets

(47,166)

(3,504)

 

The fair value of Scheme asset investments was as follows:

FY22/23

FY21/22

 

£000

£000

Diversified growth funds

28,463

65,234

Bonds and liability-driven investment funds

68,365

87,931

Cash and liquidity funds

2,770

2,615

Total assets

99,598

155,780

None of the fair values of the assets shown above include any of the Group’s own financial instruments or any property occupied, or other assets used by the Group.

All of the Scheme assets have a quoted market price in an active market with the exception of the trustees’ bank account balance.

Diversified growth funds are pooled funds invested across a diversified range of assets with the aim of giving long-term investment growth with lower short-term volatility than equities.

It is the policy of the trustees and the Group to review the investment strategy at the time of each funding valuation. The trustees’ investment objectives and the processes undertaken to measure and manage the risks inherent in the Scheme are set out in the Statement of Investment Principles.

A proportion of the Scheme’s assets is invested in the BMO LDI Nominal Dynamic LDI Fund and in the BMO LDI Real Dynamic LDI Fund which provides a degree of asset liability matching.

The net expense / (gain) recognised in the consolidated income statement was as follows:

FY22/23

FY21/22

£000

£000

Past service credit 

-

(854)

Net interest on the net defined benefit liability

665

727

Scheme administration expenses

1,414

1,211

2,079

1,084

 

The net expense / (gain) is recognised in the following line items in the consolidated income statement:

 

FY22/23

FY21/22

£000

£000

Charged to operating profit

1,242

1,000

Charged / (credited) to exceptional items

172

(643)

Other finance revenue and expense – net interest on the net defined benefit liability

665

727

2,079

1,084

 

The principal actuarial assumptions at the balance sheet date (expressed as weighted averages) were:

 

FY22/23

FY21/22

Discount rate at 31 March

4.90%

2.70%

Future salary increases

N/A

N/A

Inflation (RPI) (non-pensioner)

3.25%

3.70%

Inflation (CPI) (non-pensioner)

2.75%

3.20%

Allowance for revaluation of deferred pensions of RPI or 5% p.a. if less

3.25%

3.70%

Allowance for revaluation of deferred pensions of CPI or 5% p.a. if less

2.75%

3.20%

Allowance for pension in payment increases of RPI or 5% p.a. if less

2.90%

3.55%

Allowance for pension in payment increases of CPI or 3% p.a. if less

2.00%

2.60%

Allowance for pension in payment increases of RPI or 5% p.a. if less, minimum 3% p.a.

3.80%

3.85%

Allowance for pension in payment increases of RPI or 5% p.a. if less, minimum 4% p.a.

4.35%

4.30%

The mortality assumptions adopted at 31 March 2023 are 165% and 165% respectively of the standard tables S3PMA / S3PFA (2021: 143% / 153% of S3PMA/S3PFA respectively), year of birth, no age rating for males and females, projected using CMI_2021 converging to 1.00% p.a. (FY21/22: 1.00%) with a smoothing parameter 7.0% (FY21/22: 7.0%). The change in % applied follows an independent review prepared for the 2021 actuarial valuation.

It is recognised that the Core CMI_2021 model is likely to represent an overly cautious view of experience in the near term. As a result, management have applied judgement and the CMI_2021 model has been adopted with a w2021 and w2020 weighting parameter of 10% to represent possible future trend as a best estimate and will be kept under review in the future. These assumptions imply the following life expectancies:

2023

2022

Life expectancy for a male (current pensioner) aged 65

17.8 years

18.8 years

Life expectancy for a female (current pensioner) aged 65

20.4 years

20.9 years

Life expectancy at 65 for a male aged 45

18.7 years

19.7 years

Life expectancy at 65 for a female aged 45

21.6 years

22.0 years

It is assumed that 75% of the post A-Day maximum for active and deferred members will be commuted for cash (FY21/22: 75%).

Pension Increase Exchange take-up was estimated to be 40% on implementation in the prior year; there has been no change made to this assumption nor to the 2021 bridging pension option take-up of 40%.

 

 

 

The pension scheme liabilities are derived using actuarial assumptions for inflation, future salary increases, discount rates, mortality rates and commutation. Due to the relative size of the Scheme’s liabilities, small changes to these assumptions can give rise to a significant impact on the pension scheme deficit reported in the Group statement of financial position.

The sensitivity to the principal actuarial assumptions of the present value of the defined benefit obligation is shown in the following table:

FY22/23

FY22/23

FY21/22

FY21/22

%

£000

%

£000

Discount rate 1

Increase of 0.25% per annum

(2.41%)

 

(3,228)

 

(3.68%)

 

(6,682)

Decrease of 0.25% per annum

2.51%

3,365

3.82%

6,937

Decrease of 1.0% per annum

10.71%

14,363

16.10%

29,258

Inflation 2

Increase of 0.25% per annum

0.64%

853

1.25%

2,272

Increase of 1.0% per annum

2.77%

3,711

4.71%

8,568

Decrease of 1.0% per annum

(2.61%)

(3,499)

(5.47%)

(9,948)

Life expectancy

Increase of 1 year

4.30%

5,765

4.88%

8,862

1 At 31 March 2023, the assumed discount rate is 4.90% (FY21/22: 2.70%).

2 At 31 March 2023, the assumed rate of RPI inflation is 3.25% and CPI inflation 2.75% (FY21/22: RPI 3.70% and CPI 3.20%).

The sensitivities shown above are approximate. Each sensitivity considers one change in isolation. The inflation sensitivity includes the impact of changes to the assumptions for revaluation and pension increases.

The weighted average duration of the defined benefit obligation at 31 March 2023 is twelve years (31 March 2022: 15 years).

The life expectancy assumption at 31 March 2023 is based upon increasing the age rating assumption by one year (31 March FY21/22: one year).

Other than those specifically mentioned above, there were no changes in the methods and assumptions used in preparing the sensitivity analysis from the prior year.

The history of the Scheme’s deficits and experience gains and losses is shown in the following table:

 

FY22/23

FY21/22

£000

£000

Present value of funded obligation

(134,091)

(181,759)

Fair value of scheme asset investments

99,598

155,780

Recognised liability for defined benefit obligations

(34,493)

(25,979)

Actual loss on scheme assets

(47,166)

(3,504)

Actuarial gains due to changes in demographic assumptions

7,539

1,767

Actuarial gains due to changes in financial assumptions

38,032

(13,476)

17 Ordinary share capital

 

Ordinary shares of 5 pence each:

 

Number

of shares

£000

Issued and fully paid at 31 March 2022

73,419,193

3,671

Issued and fully paid at 31 March 2023

73,419,193

3,671

 

There are 15,974 vested shares outstanding in respect of a buyout award granted to a former director of the Company. These are yet to be issued.

There are 2,857,752 potential share options outstanding under the performance share plan at 31 March 2023 (31 March 2022: 1,517,376). No options vested during the year to 31 March 2023 (31 March FY21/22: nil) 

18 Cash generated from operations

 

FY22/23

FY21/22

£000

£000

(Loss) / Profit for the year

(3,957)

5,799

Adjustments for:

Pension scheme contributions net of costs settled by the Company

(3,287)

(3,258)

Pension scheme costs settled by the Scheme

559

 

569

Depreciation charge

7,815

6,825

Amortisation charge

211

203

Exceptional rationalisation costs

1,304

 

-

Exceptional costs arising from cancellation of future supply agreement

751

 

-

Exceptional doubtful debt and related inventory provision

896

 

-

Exceptional costs in respect to legacy claims

302

 

-

Exceptional gain in respect of retirement benefits

-

 

(854)

Exceptional profit on disposal of surplus property

(769)

 

-

Conversion of Covid-19 government support loan to grant

-

 

(2,087)

Profit on business disposal

-

(693)

Loss on disposal of intangible non-current assets

14

 

-

Share-based payment (credit) /charge

(33)

73

Financial income

(218)

(77)

Financial expense

3,967

3,066

Taxation expense

1,437

809

Operating cash flow before changes in working capital

8,992

10,375

Changes in working capital

Decrease / (increase) in inventories

1,539

(3,816)

Decrease / (increase) in contract assets

2,388

(4,708)

(Increase) / decrease in trade and other receivables

(1,656)

42

(Decrease) / increase in trade and other payables

(943)

4,549

(Decrease) / increase in contract liabilities

(2,542)

338

Cash generated from operations

7,778

6,780

19 Post balance sheet events

In December 2022, having delivered the Design and Engineering phase of the supply contract, the Group received notice from a leading global OEM customer that, due to a contraction in the end-market demand for Covid-19 testing, they would not be proceeding into the production phase of the project. On 30 May 2023, a mutually satisfactory settlement agreement was signed which largely off-sets the Group’s financial exposure arising from early termination of the contract. The Group has recognised an exceptional cost in the year to 31 March 2023 of £0.9 million, most of which is to recognise assets on balance sheet at recoverable amount, see note 6 for further details. The Group will recognise an exceptional gain in the income statement to 31 March 2024 of approximately £0.6 million. Although the details of the agreement remain confidential, full and final settlement was received on 21 June 2023.

 

On 22 June 2023 the Group’s lending bank agreed to an adjustment of the interest and the net leverage covenants related to the facilities due to mature on 30 June 2025. On 1 June 2023, a voluntary repayment of £0.4 million was made and on 30 June 2023, a further voluntary repayment of £3.3 million was made.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Information for shareholders

 

Reconciliation of non-GAAP financial measures

FY22/23

FY21/22

Notes

£000

£000

(Loss) / Profit for the period

(3,957)

5,799

Add back: profit on discontinued operations, net of tax

5

-

(693)

Statutory (loss) / profit after tax from continuing operations

(3,957)

5,106

Add back: Income tax expense from continuing operations

9

1,437

809

(Loss) / Profit before tax from continuing operations

(2,520)

5,915

Add back: Net financing charge from continuing operations

8

3,749

2,989

Operating profit from continuing operations

1,229

8,904

Add back: Exceptional items from continuing operations

6

4,710

(721)

Operating profit before exceptional items from continuing operations

5,939

8,183

Less: Covid-19 related US government grant income

 

 

-

 

(2,087)

Underlying operating profit from continuing operations

 

 

5,939

 

6,096

Add back: Amortisation of intangible assets from continuing operations

12

211

203

Underlying earnings before interest, tax and amortisation (EBITA) from continuing operations

6,150

6,299

Add back: Depreciation of property, plant and equipment from continuing operations

13

7,815

6,825

Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) from continuing operations

13,965

13,124

 

 

 

 

 

 

 

(Loss) / profit before tax from continuing operations

(2,520)

5,915

Add back: Exceptional items from continuing operations

6

4,710

(721)

Less: Covid-19 related US government grant income

 

 

-

 

(2,087)

Underlying profit before tax from continuing operations

2,190

3,107

 

 

 

 

 

 

 

Income tax expense from continuing operations

9

1,437

809

Add back: Exceptional tax credit from continuing operations

491

-

Group underlying tax expense from continuing operations

1,928

809

Group statutory effective tax rate from continuing operations

(57.0%)

13.7%

Group underlying effective tax rate from continuing operations

88.0%

26.0%

 

 

 

 

 

 

 

Cash at bank and in hand

 

10,354

12,347

Loans and borrowings - current

 

(5,046)

(2,948)

Loans and borrowings - non-current

 

(39,668)

(41,804)

 

 

 

 

 

 

Net debt

(34,360)

(32,405)

 

 

 

 

 

 

Add back: Lease liabilities

 

 

11,870

 

10,870

 

 

 

 

 

 

Net debt excluding lease liabilities

 

 

(22,490)

 

(21,535)

 

 

 

 

 

 

Information on consolidated statement of cash flows:

 

 

 

 

 

 

 

 

 

 

 

Net cash from operating activities from continuing operations

 

 

3,772

 

2,969

 

 

 

 

 

 

Net cash used in investing activities

 

 

(809)

 

(4,149)

Less: Net cash from investing activities from discontinued operations

5

 

-

 

(693)

 

 

 

 

 

 

Net cash used in investing activities from continuing operations

 

 

(809)

 

(4,842)

 

 

 

 

 

 

Net cash used in financing activities from continuing operations

 

 

(4,675)

 

(2,493)

 

 

 

 

Glossary 

CASH CONVERSION RATE

Cash generated from operations divided by EBITDA as defined below

COMPOUND ANNUAL GROWTH RATE (“CAGR”)

The geometric progression ratio that provides a constant rate of return over a time period

CONSTANT CURRENCY

Prior year translated at the current year’s average exchange rate. Included to explain the effect of changing exchange rates during volatile times to assist the reader’s understanding

FIXED ASSET UTILISATION RATIO

Revenue from continuing operations divided by tangible fixed assets

GROUP CAPITAL EXPENDITURE

Non-current asset additions

NET BANK INTEREST

Interest receivable on cash at bank less interest payable on bank loans and overdrafts. Reported in this manner due to the global nature of the Group and its banking agreements 

NET DEBT

Cash and cash deposits less loans and borrowings. Used to report the overall financial debt of the Group in a manner that is easy to understand

NET DEBT EXCLUDING LEASE LIABILITIES

Net debt, as defined above, excluding lease liabilities. Used to report the overall non-leasing debt of the Group in a manner that is easy to understand

OPERATIONAL GEARING 

Ratio of fixed overheads to sales

EBITDA

Profit before interest, tax, depreciation and amortisation

UNDERLYING

Adjusted to exclude all exceptional and separately disclosed items 

UNDERLYING EBITDA

Profit before interest, tax, depreciation and amortisation adjusted to exclude all exceptional and separately disclosed items

UNDERLYING EARNINGS PER SHARE

Earnings per share adjusted to exclude all exceptional and separately disclosed items

UNDERLYING OPERATING PROFIT

Operating profit adjusted to exclude all exceptional and separately disclosed items

UNDERLYING PROFIT BEFORE TAX

Profit before tax adjusted to exclude all exceptional and separately disclosed items

OPERATING PROFIT BEFORE EXCEPTIONAL ITEMS

Operating profit adjusted to exclude all exceptional items

RETURN ON SALES

Underlying operating profit, as defined above, from continuing operations, as a percentage of revenue from continuing operations

RETURN ON CAPITAL EMPLOYED (EXCLUDING PENSION LIABILITIES)

Return on capital employed measures the underlying operating profit for the Group, including discontinued operations, as a percentage of average capital employed, calculated as the average of the opening equity plus net debt and pension liabilities, and closing equity plus net debt and pension liabilities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR SFSEEFEDSEIW
Date   Source Headline
26th Apr 20247:00 amRNSTrading Statement
17th Apr 20247:55 amRNSDirectorate Change
15th Apr 20243:55 pmRNSHolding(s) in Company
28th Feb 20247:00 amRNSDirectorate Change
14th Feb 20247:00 amRNSStrategic Consolidation & Tucson Facility Closure
9th Feb 20241:15 pmRNSHolding(s) in Company
29th Jan 202411:09 amRNSDirectorate Change
23rd Jan 20244:48 pmRNSHolding(s) in Company
6th Dec 202310:53 amRNSHolding(s) in Company
30th Nov 20237:00 amRNSHalf-year Report
16th Nov 20237:00 amRNSNotice of Interim Results & Investor Presentation
25th Oct 20233:16 pmRNSCarclo Strategic Decision to Close Derry Facility
22nd Sep 20237:00 amRNSDirector/PDMR Shareholding
31st Aug 20234:01 pmRNSResult of AGM
31st Aug 20237:00 amRNSTrading Update
21st Aug 20231:09 pmRNSDirectorate Change
31st Jul 202311:42 amRNSAnnual Financial Report
18th Jul 20237:00 amRNSBanking covenant update
12th Jul 20237:00 amRNSFinal Results
7th Jul 20237:00 amRNSNotice of Investor Meet Presentation
23rd Jun 20237:00 amRNSBanking covenant adjustment
21st Jun 20231:08 pmRNSNotice of Results
30th May 202310:07 amRNSUpdate on contract cancellation
17th May 20238:46 amRNSHolding(s) in Company
12th May 20239:38 amRNSHolding(s) in Company
14th Apr 20237:00 amRNSTrading Statement
31st Mar 202312:50 pmRNSBanking Covenant update
9th Mar 20239:56 amRNSHolding(s) in Company
24th Feb 20237:00 amRNSDirectorate Change
6th Jan 20234:17 pmRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20221:15 pmRNSDirector/PDMR Shareholding
16th Dec 20221:11 pmRNSDirector/PDMR Shareholding
16th Dec 20221:10 pmRNSDirector/PDMR Shareholding
15th Dec 20227:00 amRNSTrading Update
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 20229:44 amRNSContract Cancellation
6th Dec 20226:29 pmRNSHolding(s) in Company - Replacement
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
30th Nov 20227:00 amRNSHalf-year Report
15th Nov 20227:05 amRNSNotice of Interim Results & Investor Presentation
15th Nov 20227:00 amRNSDirectorate Change
7th Nov 20227:00 amRNSBoard Changes
18th Oct 20227:00 amRNSTrading Update
13th Oct 20221:22 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.